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TEN GELEIDE 
Het immuunapparaat is een belangrijke factor in de bescherming 
van gewervelde dieren en de mens tegen infektieuze ziektever-
wekkers zoals bacteriën en virussen. De bescherming ontstaat 
doordat een sub-populatie van de witte bloedcellen (lymfocyten) 
in staat is om lichaamsvreemde produkten (antigenen) op een 
specifieke wijze te herkennen als niet-zelf. Lymfocyten herken-
nen een antigeen via receptoren op hun celoppervlak. De recep-
toren binden dat gedeelte van het antigeen dat er ruimtelijk in 
past, analoog aan het sleutel-slot principe, en elke lymfocyt 
heeft één type receptor. Het aantal receptortypen wordt geschat 
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op 10 per individu. 
Het immuunapparaat biedt op twee manieren bescherming, op basis 
van twee subtypen lymfocyten: de B-cellen en de T-cellen. 
De B-cellen zijn in staat tot de vorming van antistoffen. Anti-
stoffen zijn eiwitten die in bloed en andere lichaamsvloeistof-
fen voorkomen. Zij hebben dezelfde receptor specificiteit als 
de B-cel die hen produceerde waardoor ze kunnen binden aan het 
antigeen. Binding van de antistof kan op verschillende wijzen 
resulteren in de inaktivering van het antigeen. Bacteriële tox-
inen en virussen worden belemmerd in hun interaktie met doel-
witweefsels, en bacteriën kunnen worden gedood in samenwerking 
met het Complement systeem. Complement bestaat uit een serie 
eiwitten, die na aktivering door o.a. cel-gebonden antistoffen, 
een gat kunnen slaan in het celoppervlak hetgeen resulteert in 
celdood. Tevens mobiliseren de geaktiveerde complementiaktoren 
andere witte bloedcellen naar de infektieplaats. Deze cellen 
(macrofagen) kunnen het gedode materiaal opnemen en verteren. 
T-cellen maken geen antistoffen, maar zij kunnen lichaamscel-
len die door een virus zijn geinfekteerd via cel-cel kontakt 
op specifieke wijze doden. Tevens produceren zij faktoren waar-
door sommige bacteriën' die in de macrofaag voortleven en delen, 
alsnog kunnen worden afgebroken. Naast deze effektorfunkties, 
hebben T-cellen ook een zeer belangrijke regelende taak. Via 
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helper, en suppressor T-cellen wordt de intensiteit van de im-
muunrespons van zowel B-cellen als van effektor T-cellen aan-
gepast aan de aard en de intensiteit van het antigene kontakt. 
Na een eerste kontakt met antigeen duurt het 1-2 weken voordat 
de effektorfunkties volledig zijn ontwikkeld. In deze primaire 
respons echter, heeft het immuunapparaat tevens de funktie ont-
wikkeld om bij volgende kontakten sneller en adequater te rea-
geren. Dankzij deze geheugenfunktie kunnen mensen en dieren met 
succes worden gevaccineerd. Toediening van onschadelijk gemaak-
te, niet meer infektieuze bacteriën en virussen op jonge leef-
tijd induceert een primaire immuunrespons, en de daarbij ont-
wikkelde geheugenfunktie is zo afdoende dat latere infekties 
ongemerkt voorbijgaan; we zijn er immuun voor geworden. 
Het onderscheid tussen zelf en niet-zelf, het vermogen om spe-
cifiek met een bepaald antigeen te reageren, en de geheugen-
funktie daarin, zijn de fundamenten van het immuunapparaat.Dank-
zij deze eigenschappen zijn gewervelde dieren en de mens in 
staat tot een mobiel bestaan. Zij zijn gewapend tegen onbekende 
ziekteverwekkers in andere gebieden, en tegen veranderende om-
standigheden in hun eigen woonomgeving. De herkenning van vreemd 
en het destructieve antwoord daarop houdt echter ook in, dat de 
uitwisseling van weefsels en organen tussen verschillende indi-
viduen niet mogelijk is, als de kenmerken op het weefsel(Grieks: 
histos) van de donor niet compatibel (verdraagzaam) zijn met 
die van de ontvanger. In dat geval worden de weefselkenmerken 
als histocompatibiliteitsantigenen herkend, en wordt het trans-
plantaat afgestoten. 
Van de verschillende histocompatibiliteitsantigenen die bekend 
zijn, is er één systeem dat door de sterkte van de respons die 
opgeroepen wordt speciaal opvalt: het "Major Histocompatibility 
Complex" (MHC). Omdat de MHC-antigenen bovendien worden geken-
merkt door een grote diversiteit, zijn niet-verwante individu-
en binnen een soort waarlijk uniek. Dit betekent dat de ver-
schillen tussen donor en ontvanger teruggebracht kunnen worden 
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door de best passende combinatie te selekteren, maar dat de 
overeenkomst slechts volledig is bij een een-eiïge tweeling. 
Teneinde afstoting te voorkomen moet daarom het immuunapparaat 
van de ontvanger worden onderdrukt. 
De middelen die voor deze immunosuppressie ter beschikking 
staan zijn niet in alle gevallen even effektief en bovendien 
werken ze op een niet-specifieke wijze. Het totale immuunappa-
raat wordt onderdrukt, en daardoor bestaat er een verhoogde 
kans op infektieziekten en tumoren. Vanuit dat oogpunt wordt 
grote aandacht besteed aan de ontwikkeling van andere thera-
pieën. Op het laboratorium van de afdeling Nierziekten wordt 
onderzoek verricht naar de toepassingsmogelijkheden van zulke 
alternatieve therapieën. Gezien het experimentele karakter 
daarvan, wordt het onderzoek gedaan in een diermodel, waarbij 
huidtransplantaties worden verricht op muizen. In dit proef-
schrift zijn studies beschreven die gericht waren op het ver-
krijgen van een beter inzicht in het werkingsmechanisme van 
een pharmacologische en van een immunologische wijze om de 
transplantaatafstoting te onderdrukken. 
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CHAPTER 1 

INTRODUCTION 
Although the use of donor tissue to support life for others has 
been imagined since long (1), transplantation of organs and 
tissues on a large scale is a relatively new development in 
medicine. Following pioneering work in the late 1950s (2-5), 
kidney transplant programmes were initiated at various centers 
and a total of over 70.000 kidneys have been grafted today (6, 
7). In a recent survey of the results of 354 kidney transplan­
tations in Nijmegen over the period between 1968 and 1981, it 
was reported that 70% of these grafts were functioning at one 
year, dropping to 56% at 5 years (8). Patient survival was 86% 
and 76% respectively. When these figures are applied to the 
world-wide scale, it follows that 21.000 kidneys were lost one 
year after transplantation and this is most likely a gross un­
derestimation. Therefore, the situation is far from ideal and 
graft rejection remains the major problem to overcome. This 
applies even more stringently for organs such as heart and liver, 
because there is no long term artificial substitute for their 
vital functions comparable to the possibility of a return to 
haemodialysis in case of kidney graft failure. 
Rejection of organs and tissue grafts is caused by differences 
in tissue antigens between donor and recipient. These so-called 
histocompatibility antigens are encoded by several distinct ge­
netic systems, but one Major Histocompatibility Complex (MHC) 
has been identified, in all species analyzed (9). Studies in 
man (10) and in the mouse in particular (11), have revealed that 
the МНС-encoded antigens induce the most rapid graft rejection 
and that the system itself is characterized by an extreme poly­
morphism and complexity (12, 13). These phenomena have esta­
blished a unique position for the MHC, and have set it apart 
from the other so-called minor histocompatibility antigens.How­
ever, due to the polymorphism of the MHC, unrelated individuals 
are truly unique, and despite matching procedures for the most 
prominent antigenic differences, transplantation of a cadaveric 
kidney is far less efficient than a kidney graft from a living 
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relative (8) . 
The immunological basis of graft rejection was first shown by 
Medawar in 1944 using skin grafts in rabbits (14) and in sub-
sequent years, both cellular (15) and humoral (16) mechanisms 
were identified. To overcome rejection, pharmacological agents 
are used that depress the immune system. However, from the graft 
survival rates it is clear that this is not always realized. 
Moreover, besides the toxic side effects of these drugs, their 
action on the immune system is non-specific, depressing also 
the response to bacteria and viruses. Therefore, more efficient 
agents, that would in addition specifically suppress the res-
ponse to only the graft antigens, would be quite advantageous. 
Such drugs, however, have not been developed as yet. Neverthe-
less, progress has been made in the identification of non-speci-
fic immunosuppressive agents, that are more effective, and that 
may lack the toxic side effects of current therapy. The use of 
antibodies against human lymphocytes to treat rejection crises, 
which has been shown to be at least as effective as conventional 
steroid therapy, but much less dangerous (17), may be applied 
even more successfully, when appropriate monoclonal antibodies 
can be raised. In addition, the use of Cyclosporin A, a newly 
discovered fungal metabolite with profound immunosuppressive 
activity (18), has great therapeutic potential, especially now 
the molecule has been synthesized and analogous products can be 
prepared and tested (19). 
As an alternative to pharmacological agents, an attempt to spe-
cifically suppress the recipients response to donor graft anti-
gens may be provided by the immune system itself. Reminiscent 
of the feedback inhibition of enzymes by their products, anti-
bodies have been shown to exert a suppressive influence on their 
own production (20). This effect is specific. It concerns only 
the response to the immunizing antigen and does not affect the 
remainder of the immune potential of the host. Suppression by 
antibody applies also to the cellular immune response, and un-
der certain conditions, administration of antibodies to the 
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graft antigens of the donor may result in prolonged graft sur-
vival. This phenomenon, which was first described in the 1900s 
(21) has been called Enhancement (22). Its application, however, 
has been confined to experimental systems in animals, because 
first of all, enhancement is only effective in those selected 
combinations, in which the genetic disparity of donor and re-
cipient is limited. Secondly, the risk of inducing antibody-
mediated graft rejection rather than enhancement, has certainly 
prevented its clinical use, and this stresses our ignorance of 
the mechanisms underlying these phenomena. 
Therefore, experimental work in animals has continued with as 
its ultimate goal, specific immunosuppression in clinical medi-
cine, but for the short term, to gain insight into the fundamen-
tal regulatory processes which govern the immune response. 
The studies described in this thesis were designed to elucidate 
mechanisms in the induction of unresponsiveness to skin allo-
grafts in the mouse. They focus primarily on the mechanism of 
immunological enhancement, with in addition, an investigation 
on the immunosuppressive effects of Cyclosporin A. 
HISTOCOMPATIBILITY 1982 
Although originally discovered because of its role in graft re-
jection, the biological significance of the Major Histocompa-
tibility Complex of various species analyzed, greatly exceeds 
this trait. The MHC of the mouse, the H-2 system, controls some 
60 biological phenomena (23) and undoubtedly, influences on im-
mune responsiveness are the most fascinating traits. From stu-
dies on the latter phenomenon, a picture is now emerging which 
shows that the regulation of cell-cell interactions is the an-
cestral function of the MHC, with in higher vertebrates in ad-
dition, the guidance of the cellular immune response in its func-
tion of distinguishing self from non-self on cell surfaces. The-
se aspects have been described extensively (24-29), and need 
not be discussed in detail here. Excellent reviews are also a-
19 
vailable on basic immunogenetics (13,30-32) and therefore, only 
a brief outline of the H-2 complex and its significance will be 
given below. 
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Figure 1. Genetic map of chromosome 17. The l o c i , from l e f t t o r i g h t a r e : 
centromere ( · ) , brachyury (T), quaking {qk), hybrid s t e r i l i t y - 1 
(Hst-1), low (Low), fused (Fu), anury (t6), t u f t e d (tf), h i s t o -
compat ib i l i ty-39 (H-39), knobbly (Kb), kidney c a t a l a s e (Ce-2), 
h i s t o c o m p a t i b i l i t y - 3 3 (H-33), h i s tocompat ib i l i ty-2K (H-BK), h i s -
tocompatibi l i ty-2D (H-2D), Q ant igen (Qa), thymus-leukemia a n t i ­
gen (Tla), phosphoglycerate kinase-2 (Pgk-2), r e t i n a l degenera­
t ion-slow (vds), plasma p r o t e i n (Pip), complement 3-1 (C3-1), 
scopolamine modif icat ion of exploratory a c t i v i t y (Sao), acid phos-
p h a t a s e - l i v e r (Api), g lyoxylase-l (Glo-1), α-mannosidase proces­
sing 2 (Map-2), t h i n fur (thf), immune response-5 ( J r - 5 ) , e r y t h r o ­
cyte antigen-2 (Ea-2). Brackets i n d i c a t e t h a t the order of l o c i 
within the bracket i s unknown; segments i n d i c a t e t h a t the locus 
has not been mapped p r e c i s e l y and can l i e anywhere within the 
l i m i t s of the segment. (Adapted from J . Klein ( 6 9 ) ) . 
The H-2 complex i s located on chromosome 17, as i s shown in 
F i g . l . The genet ic map of the H-2 complex i t s e l f i s a matter 
for debate. T r a d i t i o n a l l y , the H-2 system i s viewed as a chro­
mosomal segment divided i n t o four regions, K, I , S, and D/L and 
the I-region further divided i n t o five subregions, I-A,I-B,I-J, 
1-Е, and I-C ( F i g . 2 ) . These d iv i s ions were made because various 
t r a i t s could be separated by crossing over. However, instead of 
c a l l i n g an indiv idual segment a locus, which i s defined as a 
segment of genet ic mater ia l coding for a s ingle polypeptide 
chain, the terms region and subregion were introduced, because 
several t r a i t s could not be separated. They mapped to the same 
chromosomal segment, and because i t was unknown whether these 
t r a i t s were contro l led by the same locus or n o t , each t r a i t was 
assigned a d i f f e r e n t locus symbol (33). Consequently, each r e ­
gion or subregion was i n i t i a l l y defined by one locus, but with 
an increas ing number of t r a i t s discovered, many more loc i were 
assigned t o them. Thus, each (sub)region c o n t r o l s several t r a i t s , 
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and each trait is presumably controlled by a separate gene pro­
duct. The traditional H-2 map is depicted in Fig.2, with afunc­
tional translation in Table I. 
Complex H -2 
Ends К D 
Regions К I S D/L 
Subregions A В 
Loci H-2K Ir-IA Ir-IB Ia-4 Ia-5 Ir-lC Ss,Sip H-2D H-2L 
Ia-1 Ia-2 Ia-3 Lad-4 
H-2A Ir-LDH H-2C 
В 
Lad-3 Lad-1 Lad-2 
Ir-(H,G) A — L 
Ir-OA 
Ir-OM 
Ir-BGG 
Figure 2: The traditional genetic map of the H-2 complex (adapted from J. 
Klein (33)) 
However, this interpretation has been challenged recently by 
the notion that a single H-2 locus is pleiomorphic, in that it 
controls a variety of traits (34). Evidence for this view was 
first of all provided by the study of H-2 mutations, which 
showed that a single mutation in a H-2K or H-2D locus, affec­
ted all traits controlled by that region (23). The same was 
true when I-region mutations were studied (35). In another ap­
proach, the expression of serologically detectable 1-Е region 
molecules was shown to correlate with the generation of cyto­
lytic T-cells, whereas with antibodies against the I-A and 1-Е 
region encoded products, immune responsiveness could be affec­
ted (36). On the basis of these and other experiments, a new 
version of the H-2 complex has been proposed (34). In essence, 
it is a highly conservative functional model of the H-2 complex, 
because only those loci have been included, of which the pro­
ducts are characterized biochemically and which fit the pre-
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Table I. Funational aspects of the traditional H-2 map a) 
Region 
Subregion I-A I-B 
I 
I-J 
D,L 
1-Е I-C 
Trait (locus) 
Serologically detectable antigens 
(H-2, Ia, SS, Sip) 
Rejection of allografts (H) 
Cell-mediated lympholysis (H) 
Mixed lymphocyte reaction (Lad) 
Control of immune response (Ir) 
(Is) 
Τ -cell marker 
Ξ 
Control of T-B cell collaboration 
Restriction of Τ -cell specificity 
Restriction of Τ -cell specificity 
Control of complement activity 
++++ 
++++ 
++ 
+ 
++++ 
+++ 
+++ 
++++ 
++++ 
++++ 
++++ 
++++ 
+ 
++++ 
++ 
+++ 
++ 
+++ 
+++ 
++++ 
++++ 
++++ 
++++ 
a) adapted from J. Klein et al. (34) 
sumed physiological function of the MHC. 
The complex is divided into class I and class II loci. The 
class I loci, K, D, and L, code each for 45 kd glycoproteins, 
which are noncovalently associated with a 12 kd 0-2 microglo-
bulin chain (37). They are expressed on nearly all cells, and 
their function is to guide cytolytic T-lymphocytes (38) . The 
class II loci, Aß and Aa, and EB and Ea, each code for 28 kd 
and 32 kd monomers respectively, which associate to form ΑβΑα 
and ΕβΕα dimers (39). They are expressed almost exclusively on 
B-cells and antigen-presenting cells (APC), and their function 
is the guidance of regulatory T-lymphocytes. 
The guidance of T-lymphocytes is effected by their recognition 
of antigen in the context of МНС-molecules, and the recogni­
tion of self-МНС may thus enable the identification of non-self. 
The extreme polymorphism of the class I and class II loci is 
than from a teleologie viewpoint a most appropriate phenomenon, 
because polymorphism, and thus different capabilities of immu­
nological responsiveness between individuals, protects the spe­
cies from infections agents resembling self. Thus, MHC-polymor-
phism ensures the survival of the species, at the sacrifice of 
the individual. 
It is not clear how the associative recognition of antigen and 
MHC-molecules by T-lymphocytes leads those cells to respond or 
not (40-42). In one view, it was postulated that defective re­
activity of T-helper cells was due to defects in the physical 
association of class II molecules with antigen (43). Thus, ac­
cording to this hypothesis, unresponsiveness functioned at the 
level of the antigen-presenting cell (44). Recently, however, 
this view was challenged by the observation that APC'с from 
non-responder mice were perfectly able to present at least the 
antigen tested to allogeneic T-cells (45). This suggested that 
in the syngeneic situation unresponsiveness functioned at the 
level of the T-cells, and might be caused by deficiencies in 
their receptor repertoire. These deficiencies might result from 
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the thymic education of T-cells and, as one of several possi­
bilities, the selection of receptor repertoires for non-self 
MHC. In that case, T-cells do not recognize self, but "altered-
self", and antigens which resemble self-МНС cannot be seen. 
Alternatively, unresponsiveness at the T-cell level might also 
be explained by the operation of yet another MHC-restricted 
response, the functioning of T-suppressor cells. Which of these 
interpretations will prove to be correct awaits further expe­
rimentation, but the importance of the MHC for the regulation 
of the immune response is indisputable, and the unravelling of 
the delicate interplay of complex regulatory circuits must ul­
timately reveal the final aesthetic simplicity of the immune 
system. 
The new version of the H-2 complex may be the H-2 proper, ac­
cording to what the function of МНС-molecules is thought to be. 
However, it is not claimed to be the final version. Firstly, 
the Qa and Tla loci, which encode products that have been 
termed class IV (27), may be part of the complex because struc­
turally, and perhaps also functionally, they resemble the class 
I loci (37). The same is true for new, recently identified K-
and D-region encoded molecules (46). Secondly, unique I-region 
encoded products have been detected on mature functional T-
cells (47), whereas I-J controlled determinants are expressed 
on suppressor T-cells and on factors derived from these lympho­
cytes (48). It may be speculated that whereas class I molecu­
les guide cytolytic effector functions, and class II molecules 
initiate functions on the APC-T cell, and T-B cell level, these 
molecules (class V?) guide T-T interactions at the regulatory 
level. Ample evidence has also been produced for the existence 
of carbohydrate defined I-region associated determinants (49) 
but their significance for the H-2 related functions remains 
also to be established. The same holds for the S-region which 
controls complement components (class III). In addition to 
these serological findings, analysis at the DNA-level progres­
ses rapidly, and the presence of several different genes in the 
D -region has been reported (50). Therefore, a less conserva-
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tive new version of the mouse H-2 complex maybe visualized as is 
shown inFig.3. The H-2mapthus remains "as unstable as always" 
(23), but this merely reflects the prime importance of the stu­
dy of theMHC, aswas emphasized in 1980 by the Nobel Prize award 
in Physiology and Medicine, toB.Benacerraf, J.Dausset and G.D. 
Snell, who, amongst others, pioneered in these investigations. 
H-2 COMPLEX 
LOCUS 
CHROMOSOME 17 
memorane 
I 
К 
(Τ?) ш 
Αα Ар Ер J Εα 
k M 
ж 
C2 
C4 
BI 
ш 
Ss Sip Bf D L M ОагОазОаіТіа 
A A A m m m α—a—о—o— 
l· 
5 ^ ^ 
>\/J/l 
ZBh Sfc 3?h 
ß2 mtcroglobui in 
CHROMOSOME 2 
Figure 3. A new version of the H-2 complex (adapted from J. Klein (70)) 
The s t u d i e s d e s c r i b e d in t h i s t h e s i s were performed mainly i n 
a mouse s k i n a l l o g r a f t model , i n which donor and r e c i p i e n t s 
were i n b r e d and g e n e t i c a l l y w e l l d e f i n e d . The H-2 h a p l o t y p e s 
of t h e s e mouse s t r a i n s a r e shown i n Table I I , and t h e i r geno-
t y p e s i n Table I I I . 
Table I I . E-2 haplotypes of the mouse strains used 
Haplotype: 
Strains: 
a 
A/HeJ 
BIO.A 
b 
C57BL/6J 
C57BL/10 
C57BL/R1J 
C57BL/6 nu/nu 
В10.LP nu/nu 
d 
BlO.D2/Sn-new 
Bl0.D2/Sn-old 
BALB/c 
BALB/cByKh 
BALB/c nu/nu 
BALB/cH-2 d m 2 a 
к 
BIO.BR 
BALB.K 
C3H nu/nu 
a) BALB/cH-2 i s a mutant which does not express the H-2L molecule 
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Table III. H-2 genotypes of the mouse strains used 
strain 
A/HeJ 
C57BL 
B10.D2 
BALB/cH-
B10.BR 
BIO.A 
BIO.LP 
BALB/c 
2dm2 
BALB.K C3H 
haplotype 
a 
b 
d 
d 
к 
К 
к 
b 
d 
d 
к 
Αα 
к 
b 
d 
d 
к 
Aß 
к 
b 
d 
d 
к 
ЕВ 
к 
b 
d 
d 
к 
J 
к 
b 
d 
d 
к 
Εα 
к 
b 
d 
d 
к 
S 
d 
b 
d 
d 
к 
D 
d 
b 
d 
d 
к 
L 
d 
b 
d 
-
к 
ENHANCEMENT OF MOUSE SKIN ALLOGRAFTS 
Enhancement may be viewed as an anomalous immunological pheno­
menon. The growth of an allograft in the presence of antibo­
dies directed to the graft antigens is not inhibited, but fa­
voured instead. This phenomenon, and the hypotheses which have 
been proposed to explain it have been excellently reviewed over 
the years (51-59) and therefore, only a frame will be pictured 
here. 
First of all, understanding of the enhancing process was in­
creased considerably when it was demonstrated for mouse skin 
allografts, that the protective effect of alloantibodies was 
changed into a destructive one, in the presence of a heterolo­
gous complement source (60). This suggested that the protec­
tive effects of alloantibodies could come to light because of 
an inefficiency of mouse complement to mediate acute rejection. 
This proved to be correct in subsequent studies (61). It also 
offered the possibility for the separate study of protective 
and destructive effects, in the same transplantation model. 
Passive enhancement could be induced by administration of allo-
antisera on days 0, 2, and 4 after grafting, whereas acute an­
tibody-mediated rejection (AAR) was evoked by the same alloan­
tibodies, but administered simultaneously with rabbit comple­
ment, on day 7 after grafting. 
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With these protocols, protective and destructive activities 
were distinguished following the separation of alloantibodies 
in different immunoglobulin subclasses, and according to their 
anti-class I and anti-class II specificities. The results can 
be summarized as follows: 
1. AAR is mediated by complement fixing antibodies with speci-
ficity for class I antigens (62,63). 
2. Enhancement is primarily mediated by alloantibodies with 
specificity for class II antigens (63), but also by anti-
class I antibodies, although with the latter, the effects 
are small (64,65). 
3. Both IgG2 and IgGl antibodies are enhancing but on the ba-
sis of protein injected, IgGl is less efficient than IgG2 
(62). 
Thus, these findings demonstrated that non-destructive enhan-
cing antibody preparations should consist of either anti-class 
II sera, or of non-complement fixing IgGl antibodies. Moreover, 
the apparent differences in the enhancing capacities of IgGl 
and IgG2 suggested that the Fc-fragment of enhancing antibodies 
played a crucial role, and might be involved in their ultimate 
effect. This proved to be true, because F(ab')2 fragments were 
completely devoid of enhancing activities, as was demonstrated 
using skin (66) and tumor allografts (67). 
The significance of the Fc-part of enhancing antibodies for the 
mechanism of enhancement formed the basis of most of the stu-
dies described in this thesis, as is further detailed below. 
OBJECTIVES OF THIS STUDY 
The findings that enhancement is Fc-dependent raised the ques-
tion how this would be functionally linked to the induction of 
immune suppression. Since enhancement is specific, the interac-
tion of enhancing antibodies with the graft antigens is clearly 
implicated and, as a consequence, antigen-antibody complexes 
might constitute the active principles in enhancement. Studies 
addressing this possibility are described in Chapter 2. 
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It was also asked how antigen-antibody complexes might exert 
their effect. As is shown in Fig.4 the possibility was consi­
dered that antigen-antibody complexes might be bound by speci­
fic antigen-reactive lymphocytes of the recipient, and that 
this would result in the inactivation of these cells, by a Fc-
dependent mechanism. The Fc-dependent effector mechanisms res­
ponsible for inactivation might then be delineated using va­
rious immunoglobulin (sub)classes. In Chapter 3, studies are 
described in which the enhancing capacities of IgG and IgM an­
tibodies were correlated with their opsonizing capacities. 
Fc-DEPENDENT 
ARC INACTIVATION BY: 
1. COMPLEMENT ? 
2. PHAGOCYTOSIS ? 
3. ADCC OR OTHER ? 
Figure 4. Hypothetical scheme for the i n a c t i v a t i o n of a n t i g e n - r e a c t i v e c e l l s 
(ARC) by ant igen-ant ibody complexes, as a mechanism for immunolo­
g i c a l enhancement. Closed symbols r e p r e s e n t the a n t i g e n i c d e t e r ­
minants on r e l e a s e d g r a f t ant igen; "}— r e p r e s e n t s enhancing an­
t ibody; ADCC: antibody dependent . c e l l u l a r c y t o t o x i c i t y 
Since enhancement r e f l e c t s the suppression of the c e l l u l a r im­
mune response, i t was a l so asked whether the humoral response 
could be suppressed by a l l o a n t i b o d i e s in a s imi lar Fc-dependent 
manner. For t h i s purpose, the antibody response of nude mice 
to a l logeneic and xenogeneic r a t skin gra f t s was s tudied and 
the e f fects of IgG and IgM ant ibodies were analyzed, as i s des­
cribed in Chapter 4. 
Studies on the e f fect s of IgGl and IgG2 a l l o a n t i b o d i e s in en­
hancement and opsonization are described in Chapter 5. In pre­
vious s t u d i e s (62), IgGl was shown t o be l e s s e f fect ive than 
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IgG2 in enhancement, but this comparison was based on the 
amounts of protein injected. Since IgGl alloantibodies are not 
destructive because they cannot fix complement, it was impor-
tant to re-establish their enhancing capacity, but this time 
on the basis of specific antibody activity. In addition, en-
hancement by IgGl should give further information on the role 
of complement in the immune complex-mediated inactivation of 
antigen-reactive cells. 
A different approach for the study of various immunoglobulin 
(sub)classes in enhancement is described in Chapter 6. Instead 
of tedious isolation procedures, the use of monoclonal antibo-
dies offered the possibility to directly select for the rele-
vant antibody (sub)classes, and their specificity. In addition, 
the use of monoclonal antibodies could provide valuable insight 
into the mechanism of enhancement; in order to interact with 
antigen-reactive cells, antigen-antibody complexes should dis-
play free antigenic determinants, the extent of which can be 
varied by using mixtures of various monoclonal antibodies. 
Up till now, we have studied the induction of specific unres-
ponsiveness by antibodies. However, an entirely different ap-
proach could not be neglected. As mentioned in the introduc-
tion, the recently discovered fungal metabolite. Cyclosporin 
A (CyA), displays profound immunosuppressive activities. Most 
remarkable however, is its specificity for T-lymphocytes and 
initial studies in the rabbit showed that a short course of 
CyA, induced the long-term acceptance of kidney grafts (68). 
As the effects were specific, it was proposed that CyA acted 
by the elimination of T-lymphocytes, specifically activated by 
the graft antigens. Consequently, a short course of CyA might 
deplete specific lymphocyte clones, and newly differentiated 
stem cells could see the graft as self. This hypothesis was 
tested using mouse skin allografts, as is decribed in Chapter 
7. 
29 
REFERENCES 
1. The Holy Bible, Genesis 2: 21 
2. Hume DM, Merrill JP, Miller BF, Thorn GW: J Clin Invest 34: 327, 1954 
3. Murray JE, Merrill JP, Harrison JH: Surg Forum 6: 432, 1955 
4. Murray JE, Merrill JP, Dammm GJ, Dealy JB, Watter CW, Brooke MS, Wilson 
RE: Surgery 48: 272, 1960 
5. Hamburger J, Vaysse J, Crosnier J, Auvert J, Lalanne CM, Hopper J: Amer 
J Med 32; 854, 1962 
6. Rapaport FT: Transplant Proc 13: 6, 1981 
7. Persian GG: personal communication 
8. Berden JHM, Hoitsma AJ, Buys WCAM, Reekers P, Skotmcki SH, Debruyne 
FMJ, Koene RAP: Neth J Med 25: 73, 1982 
9. Götze D, editor: The Major Histocompatibility System in Man and Animals, 
Springer-Verlag, Berlin, Heidelberg, New York, 1977 
10. Van Rood JJ, Persi]n GG, Paul LC, Cohen B, Lansbergen Q, Goulmy E, Claas 
FHJ, Baldwin W, van Es LA: Transplant Proc 13: 909, 1981 
11. Counce S, Smith P, Barth R, Snell GD: Ann Surg 144: 198, 1956 
12. Albert E, Götze D: In ref. 9, page 7 
13. Klein J: Biology of the Mouse Histocompatibility^ Complex, Springer-
Verlag, Berlin, Heidelberg, New York, 1975 
14. Medawar PB: J Anat Lond 78: 176, 1944 
15. Mitchison NA: Nature 171: 267, 1953 
16. Stetson CA· Adv Immunol 3: 97, 1963 
17. Hoitsma AJ, Reekers P, Kreeftenberg GJ, Van Lier HJJ, Capel PJA, Koene 
RAP: Transplantation 33: 12, 1982 
18. Morris PJ: Transplantation 32: 349, 1981 
19. Green C: Immunol Today 3; 121, 1982 
20. Uhr JW, Möller G: Adv Immunol 8: 81, 1968 
21. Flexner S, Jobling JW: Proc Soc Exp Biol Med 5: 16, 1907 
22. Casey AE: Proc Soc Exp Biol Med 31: 663, 1934 
23. Klein J: Adv Immunol 26: 56, 1978 
24. Klein J: In ref. 9, page 339 
25. Klein J: CIBA Found Symp 68: 19, 1978 
26. Klein J: Immunology '80, Progress in Immunology 4: 239, 1980 
27. Benacerraf B· Science 222: 1229, 1981 
28. Snell GD- Science 223: 172, 1981 
30 
29. Dausset J: Science 213: 1469, 1981 
30. Festenstein H, Demant Ρ: In Current Topics in Immunology, no. 9, J.Turk, 
editor. Edward Arnold Ltd, 1978 
31. David CS: In ref. 9, page 255 
32. Shreffler DC, David CS: Adv Immunol. 20: 125, 1975 
33. Klein J: Immunogenetics S: 377, 1979 
34. Klein J, Juretic A, Baxevanis CN, Nagy ZA: Nature 252: 455, 1981 
35. McKenzie IFC, Morgan GM, Sandrin MS, Michaelides MM, Melvold RW, Kohn 
HI: J Exp Med 150: 1323, 1979 
36. Nagy ZA, Baxevanis CN, Ishii N, Klein J: Immunol Rev 60: 59, 1981 
37. Vitessa ES, Capra JD: Adv Immunol 26: 147, 1978 
38. Zinkernagel RM, Doherty PC: Adv Immunol 27: 51, 1979 
39. Uhr JW, Capra JD, Vitetta ES, Cook RG: Science 206: 292, 1979 
40. Nagy ZA, Klein J: Immunol Today 2: 228, 1981 
41. Shevach E: Immunol Today 3: 31, 1982 
42. Rosenthal AS: Immunol Today 3: 33,1982 
43. Benacerraf B: J Immunol 120: 1809, 1978 
44. Rosenthal AS, Schwartz RH, Yano A, Paul WE: Immunol Rev 40: 135, 1978 
45. Ishii N, Nagy ZA, Klein J: Nature 295: 531, 1982 
46. Démant Ρ, Iványi D, Oudshoorn-Snoek M, Calafat J, Roos ΜΗ: Immunol Rev 
60: 5, 1981 
47. Hiramatsu К, Ochi A, Miyatani S, Segawa A, Tada T: Nature 296: 666, 1982 
48. Tada T, Okumura K: Adv Immunol 28: 1, 1979 
49. Higgins TJ, Parish CR, Hogart PM, McKenzie IFC, Hämmerling GJ: Immuno-
genetics 11: 467, 1980 
50. Steinmetz M, Frelinger JG, Fisher D, Hunkapillar T, Perreira D, Weiss-
man S, Uehara H, Nathenson S, Hood L: Cell 24: 125, 1981 
51. Kaliss N: Cancer Res 18: 992, 1970 
52. Snell GD: Surg Gynaecol Obstet 130: 1109, 1970 
53. Voisin GA: Progr Allergy 15: 328, 1971 
54. Feldman JD: Adv Immunol 15: 167, 1972 
55. Carpenter CB, d'Apice AJF, Abbas AK: Adv Immunol 22: 1, 1976 
56. Voisin GA: Immunol Rev 49: 3, 1980 
57. Morris PJ: Immunol Rev 49: 93, 1980 
58. Stuart FP, McKearn TJ, Weiss A, Fitch FW: Immunol Rev 49: 127, 1980 
59. Hutchinson IV: Immunol Rev 49: 167, 1980 
60. Koene RAP, Gerlag PGG, Hagemann JFHM, Van Haelst ÜJH, Wijdeveld PGAB: 
31 
J Immunol 111: 520, 1973 
61. Berden JHM, Capel PJA, Koene RAP. Eur J Immunol 5: 158, 1978 
62. Jansen JLJ, Koene RAP, Van Kamp GJ, Tamboer WPM, Wijdeveld PGAB: J 
Immunol 115: 387, 1975 
63. Jansen JLJ, Kbene RAP, Van Kamp GJ, Hagemann JFHM, Wijdeveld PGAB: J 
Immunol 115: 392, 1975 
64. De Waal RMW, Capel PJA, Koene RAP: J Immunol 124: 719, 1980 
65. Capel PJA, De Waal RMW, Démant Ρ, Koene RAP: Transpl Proc 13: 649, 1981 
66. Capel PJA, Tamboer WPM, De Waal RMW, Jansen JbJ, Koene RAP: J Immunol 
122: 421, 1979 
67. De Waal RMW, Cornelissen IMHA, Capel PJA, Koene RAP: J Immunol 123: 
1353, 1979 
68. Green CJ, Allison AC, Precious S: Lancet 1: 123, 1979 
69. Klein J: Science 203: 516, 1979 
70. Klein J: Immunol Today 2 (10), 1981 
32 
CHAPTER 2 
EFFECTS OF ALLOANTIBODY, DONOR ANTIGEN, AND ANTIGEN-ANTIBODY 
COMPLEXES ON THE SURVIVAL OF MOUSE SKIN ALLOGRAFTS 
Simon P.M. Lems, Peter J.A. Capel and Robert A.P.Koene 
From the Department of Medicine, Division of Nephrology 
Sint Radboud Hospital, University of Nijmegen, The Netherlands 
SUMMARY 
Enhancement of mouse skin grafts by alloantibodies was compa-
red with the effects of donor antigen and antigen-antibody com-
plexes. Spleen cell membranes and detergent extracts thereof 
were used as sources of alloantigen. These preparations inhi-
bited the lymphocytotoxicity of alloantibodies in vitro, and, 
depending on the route of administration and their form, they 
specifically primed prospective skin graft recipients fora se-
condary response, but did not induce active enhancement. Pas-
sive enhancement was readily demonstrated by the administra-
tion of alloantibodies at the time of grafting. However, after 
their incubation with alloantigen in vitro, to form antigen-
antibody complexes, the enhancing effects of antibody alone 
were antagonized and not augmented. The same held true when, 
by the separate administration of alloantigen and alloantibody 
putative complexes were allowed to be formed in vivo. These re-
sults indicate that for the enhancement of mouse skin allo-
grafts, the use of alloantibody alone is superior to the admi-
nistration of antigen-antibody complexes or donor antigen. 
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INTRODUCTION 
Pretreatment of prospective tumor graft recipients with donor 
antigen may result in prolonged graft survival, and anti-donor 
antibodies have been identified as one of the active principles 
(1-3). This phenomenon of Immunological Enhancement, which ex-
tends to normal tissues as well, can also be induced by the pas-
sive administration of alloantibody. The latter procedure is 
more reliable because active immunization may easily lead to ac-
celerated graft rejection, due to the induction of cell-media-
ted immunity. 
The role of antibodies in this type of immunoregulation may be 
explained by the assumption that immune complexes of anti-donor 
antibody and graft antigens interfere with immunocompetent cells 
of the host. Evidence for this originates from tumor systems, 
in which blocking of cell-mediated cytotoxicity by complexes in 
vitro was demonstrated (4). Immunosuppressive effects of anti-
gen-antibody complexes have also been demonstrated in organ 
transplantation in vivo. Indirect evidence stems from the ob-
servations that the combined treatment with donor antigen and 
anti-donor antibody is more effective than the administration 
of either component alone (5,6), whereas similar effects have 
been reported with preformed complexes using liver grafts in 
baboons (7), and heart allografts in the rat (8,9). 
If enhancing antibody acts by means of complexing with donor 
antigen in vivo, it might be expected that the size and the 
composition of these complexes varies with time, and that this 
influences their effectiveness. Thus, treatment with stable pre-
formed antigen-antibody complexes might be superior to the ad-
ministration of enhancing antibody alone. Therefore, we have 
investigated the effect of antigen-antibody complexes, in compa-
rison with antibody or antigen alone. The results indicate that 
for the enhancement of mouse skin allografts, the use of allo-
antibody is superior to either donor antigen, or antigen-anti-
body complexes. 
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MATERIALS AND METHODS 
Breeding pairs of B10.D2/Sn-new (H-2d) , BIO.BR (H-2 ), A/HeJ and' BIO.A 
(H-2a), and C57BL/10 and C57BL/6J (H-2 ) were originally obtained from the 
Jackson Laboratory, Bar Harbor, Me. C57BL/Rij (H-2 ) originated from the 
Radiobiological Institute TNO, Rijswijk, The Netherlands. (C57BL/Rij χ 
A/HeJ)Fl = B6AF1 and (C57BL/6J χ A/HeJ)Fl = B6JAF1 were raised in the labo­
ratory. 
Alloantisera were prepared by weekly i.p. injections with a suspension of 
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5 χ 10 lymphoid cells in Complete Freund's Adjuvant (CFA), as described 
earlier (10). Pooled ascites was heat-inactivated (56 C, 30 min), precipi­
tated with (NH4)2S04 and after solubilization sterilized by passage through 
membrane filters (Schleicher and Schüll, Dassel, West Germany) with decrea-
sing pore sizes ranging from 8 μ to 0.2 μ. Rabbit anti-mouse lymphocyte se­
rum (RAMLS) was prepared as described previously (10). 
Spleen cell membranes were prepared essentially as described by Shimida and 
Nathenson (11), and solubilized with sodium deoxycholate (DOC) according to 
Cresswell (12). DOC-extracts were dialyzed extensively against buffered sa­
line to remove detergent, and stored at -80 C, like the membranes. Total 
protein was determined by the method of Lowry et al (13) using bovine serum 
albumin as a standard. 
Antigenic activity was determined by inhibition of lymphocytotoxicity. In 
the case of B10.D2 alloantigens, 25 μΐ anti-BlO.D2 ascites, diluted to lyse 
80-90% of B10.D2 spleen cells, were preincubated (37 C, 30 min) with a 25 
μΐ dilution series of alloantigen, and thereafter this mixture was incuba­
ted (370C, 30 min) with 25 μΐ B10.D2 spleen cells (5 χ 106/ml) and 25 μΐ 
diluted (1:3) rabbit serum as a complement source. Antigenic activity is 
expressed as Inhibition Units (I.U.). One I.U. is defined as the reciprocal 
titer of 25 μΐ of alloantigen. 
Transplantation of tail skin was carried out by a modification of the "fit­
ted graft" technique, as described earlier (14). Each experimental group 
consisted of at least 5 mice. 
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RESULTS 
Effects of donor antigen. Membranes and detergent extracts 
thereof (DOC-extract) were used as sources of alloantigen. The 
results of a representative isolation, using 100 B10.D2 mice, 
are shown in Table I. 
Table I. Isolation of alloantigens 
Preparation Total protein Specific activity Recovery (%) Purification 
(mg) (units/mg) 
315 
610 
705 
1890 
spleen cells 
membranes 
DOC-extract 
lectin eluate 
660 
210 
160 
15 
protein 
100 
32 
24 
2 
activity 
100 
62 
54 
14 
1 
1.9 
2.2 
7 
Membranes and DOC-extract displayed specific antigenic activi-
ty in vitro, as was measured by the inhibition of lymphocyto-
toxicity (Fig.l). DOC-extract could be further purified by affi-
nity chromatography on a lentil-lectin column, as described by 
De Waal et al (15), but this was accompanied by a 4-fold loss 
of material (Table I). Moreover, extensive dialysis resulted 
in a gel-like preparation, most likely due to the loss of sta-
bilizing protein, and therefore, only the membranes and DOC-
extract were analyzed in vivo. 
Pretreatment of B6AF1 or BIO.A recipients with B10.D2 alloanti-
gen had either no noticeable effect on the survival of B10.D2 
skin, or it resulted in sensitization. These effects depended 
on the form of the antigen, the route, and the time of admini-
stration. Priming for a secondary response was most prominent, 
if 28 days before transplantation a first B10.D2 skin graft was 
applied (Table II). Control survival times of 10.9 days were 
curtailed to < 7 days, because after removal of the band-aid the 
majority of test grafts was not healed in. Irradiated (2000 rads) 
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Figure 1. Speci f ic i n h i b i t i o n of c y t o t o x i c i t y by B10.D2 membranes ( · - · ) and 
B10.D2 DOC-extract ( A - A ) . I n h i b i t i o n was t e s t e d using d i l u t e d 
(1:300) B6AF1 anti-Bl0.D2 a s c i t e s with B10.D2 spleen c e l l s (c los­
ed symbols), and B10.D2 anti-C57BL/Rij (1:200) with C57BL/RÌJ 
spleen c e l l s as s p e c i f i c i t y con t ro l (open symbols) 
spleen c e l l s induced s imi lar s e n s i t i z a t i o n , but by c o n t r a s t , an 
equivalent ant igenic amount of membranes or DOC-extract did not . 
Only emulsified in CFA, these prepara t ions spec i f i c a l l y primed 
the hos t , when they were administered 28 days before graf t ing 
(Table I I ) . Membranes were also non-immunogenic when in jec ted 
i . v . a t the time of g ra f t ing , even in higher doses (not shown). 
However, a f t e r i . p . in jec t ion shor t ly before g ra f t ing , s e n s i t i -
zation was apparant , but t h i s e f fec t t r a i l e d of when the i n t e r -
val between immunization and t r ansp lan ta t ion became la rger (Ta-
ble I I I ) . These e f fec t s were not seen with DOC-extracts, which 
were non-immunogenic a t any time, whether in jec ted without ad-
juvant i . p . , or i . v . I t i s evident from these findings tha t an-
t igen pretreatment never resu l ted in prolonged gra f t su rv iva l , 
due to ac t ive enhancement. 
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Table il. Survival of B10.D2 skin grafted onto BIO.A reaipients after dif­
ferent forms and routes of donor antigen administration 28 days 
before grafting. 
MST + S.D. (days a) 
route of administration 
i.p. i.p. + CFA 
None 
B10.D2 skin graft 
B10.D2 spleen cells (2.107) 
B10.D2 membranes 
B10.D2 DOC-extractb) 
10.9 + 1.1 
< 7 
7.8 + 1.1 
11.0 + 1.2 
10.1 + 1.0 
6.8 + 1.1 7.6 + 1.1 
11.6 + 1.1 8.2 + 1.1 
9.8 + 1.1 8.0 + 1.0 
a) Median Survival Time + Standard Deviation (applies also to Tables III-IX) 
b) 2 χ 10 B10.D2 spleen cell equivalents 
Table III. Effects of i.p. injected B10.D2 membranes on the survival of 
B10.D2 skin grafted onto BIO.A recipients. Influence of dose 
and time interval between immunization and grafting. 
Treatment 
None 
Membranes i.p. 
5 μΐ 
25 μΐ 
125 μΐ 
-7, -5, -3 
10.9 + 1.1 
8.1 + 1.1 
7.0 + 1.2 
7.0 + 1.2 
P a ) 
< 0.005 
< 0.005 
< 0.005 
MST + S.D. (days) 
-17, -15, -13 
10.9 + 1.1 
9.9 + 1.2 
10.5 + 1.1 
9.5 + 1.2 
a) 
Ρ 
N . s .
c ) 
N.S. 
N.S. 
a) Level of significance (Student's t-test) in comparison with untreated 
controls 
b) 1 μΐ is equivalent to 10 spleen cells 
c) N.S., not significant 
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Effects of allcantibody. The e f f i c i e n c y of B6AF1 anti-B10.D2 
a l l o a n t i b o d i e s was analyzed by induct ion of p a s s i v e enhancement 
of B10.D2 sk in graf ted onto BIO.A or B6AF1 r e c i p i e n t s . As i s 
demonstrated in Table IV, i . p . treatment of B6AF1 r e c i p i e n t s on 
day 0, 2, and 4 a f t e r gra f t ing r e s u l t e d in a dose-dependent pro­
longat ion of gra f t surv i va l from 10.9 t i l l 19.9 days. However, 
when a l loant ibody was i n j e c t e d before g r a f t i n g , l i t t l e or no en­
hancement could be demonstrated. Using BIO.A r e c i p i e n t s , iden­
t i c a l r e s u l t s were obtained {data not shown). 
Table IV. Passive enhanaement by B6AF1 anti-B10.D2 alloantibody in B6AF1 re­
cipients of B10.D2 skin grafts. Influence of dose and time interval 
MST + S.D. (days) 
T r e a t m e n t 
0 , 2, 4 - 7 , - 5 , - 3 - 1 4 , - 1 2 , -10 
None 1 0 . 9 + 1.1 
B6AF1 a n t i - B 1 0 . D 2 serum 
1 μΐ 12 .6 + 1.2 
2 μΐ 1 5 . 5 + 1.1 
5 μΐ 1 7 . 3 + 1.1 13.2 + 1.0 
15 μΐ 18 .1 + 1.1 
50 μΐ 19 .9 + 1.2 13 .6 + 1.1 12.2 + 1.0 
Effects of antigen-antibody complexes. On the basis of the re­
sults obtained with antigen or antibody alone, the effect of 
complexes was analyzed in several ways. Since antibody alone in­
duced significant enhancement, it was analyzed whether complex-
formation could augment this effect by using limited amounts of 
alloantibody and a non-immunogenic route of antigen administra­
tion. Using different amounts of membranes and two doses of allo­
antibody to arrive at varying ag:ab ratio's, we could demonstra­
te that complex formation did not augment enhancement, but anta­
gonized it (Table V). 
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Table V. Effect of preformed inmune complexes injected i.V. on days 0, 23 
and 4 after grafting of B10.D2 skin onto B6AF1 recipients 
Treatment Ag:Ab ratio MST + S.D. 
(days) 
2 μΐ anti-B10.D2 
+ 0,2 μΐ membranes 
+ 2 μΐ 
+ 20 μΐ 
25 μΐ anti-BIO.D2 
+ 2 yl membranes 
+ 25 μΐ 
+ 125 yl " 
1 
1 : 
0 
1 
1 
5 
10 
1 
1 
10 
1 
1 
13.4 + 1.0 
12.2 + 1.0 
12.4 + 1.2 
12.2 + 1.2 
17.3 + 1.1 
14.5 + 1.1 
12.8 + 1.1 
12.0 + 1.2 
In a second protocol use was made of the finding that antibo­
dies administered before grafting did not induce enhancement, 
whereas DOC-extract injected i.p. was non-immunogenic. However, 
as is shown in Table VI, graft survival was not prolonged sig­
nificantly. If instead of DOC-extract, membranes were used un­
der these conditions, sensitization resulted at anagtab ratio of 
5:1 (TableVI), confirming the results depicted inTable III. 
Negative results were also obtained in a different donor-reci­
pient combination, BIO.BR+B10.A, using complexed BIO.BR DOC-
extract injected i.V. 17 days before skin grafting (Table VII). 
Since a combination of antigen-pretreatment with anti-lympho­
cyte serum was reported to be highly effective in the prolon­
gation of skin graft survival (16), the effects of antigen or 
complexes were also analyzed in immunosuppressed BIO.A reci­
pients, but these results were also negative (Table VII). 
In another approach, B10.D2 antigen and alloantibody were injec­
ted separately, in an attempt to induce complex formation in 
vivo. It was reasoned that the injection of B10.D2 DOC-extract 
intracutaneously as a depot in Incomplete Freund's Adjuvant 
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Table Vi. Effect of preformed immune aomplexes inseoted i.p. on days -?, 
-5, -3 on the survival of B10.D2 skin grafted onto B6AF1 reci-
pients 
Treatment Ag:Äb ratio MST + S.D. 
(days) 
1 μΐ anti B10.D2 
+ 15 μΐ membrane extract 
+ 30 μΐ 
+ 60 μΐ 
+ 150 μΐ " 
+ 1 μΐ membranes 
+ 5 μΐ 
15 
30 
60 
150 
1 
5 
10.9 + 1.1 
11.2 + 1.1 
12.2 + 1.1 
12.6 + 1.1 
10.7 + 1.1 
10.2 + 1.1 
7.6 + 1.1 
Table VII. Effect of the i.V. administration of antigen and antigen-antibo­
dy complexes in normal, and in immunosuppressed female BIO.A 
recipients of BIO.BR skin 
Treatment Ag:Ab 
ratio 
MST + S.D. 
RAMLS + RAMLS 
a) 
b) 
None 
BIO.BR DOC extract" 
+ anti BIO.BR serum 
uC) 
11.2 + 1.1 45.2 + 1.4 
11.9 + 1.2 37.3 + 1.2 N.S 
11.1 + 1.1 36.6 + 1.2 N.S. 
d) 
d) 
a) Rabbit anti-mouse lymphocyte serum (0.25 ml) was administered on days 
0, 2, and 4 after grafting 
b) Level of significance (student's t-test) in comparison with RAMLS trea­
ted controls 
c) 160 μΐ BIO.BR DOC-extract was injected i.V. 17 days before grafting 
d) N.S., not significant. 
might be comparable to a skin graft. However, using C57BL/10 
recipients in these experiments, higher doses of antigen cur-
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tailed graft survival, whereas the lowest amount tested (15 μΐ) 
induced weaker effects than enhancing antibody alone, given at 
the time of grafting (Table VIII). Also with lymphocytes injec­
ted i.v. 11 days, and alloantibody i.V., 10 days before graf­
ting, a protocol efficient in the enhancement of rat renal al­
lografts (6), sensitization was apparent using higher doses, 
whereas with lower amounts of cells, no enhancement could be 
induced (Table VIII). 
Finally, the effect of established enhancing conditions on the 
survival of a second skin graft was evaluated, in order to gain 
insight into the dynamics of the enhancing process. Enhancing 
conditions were induced by the administration of alloantibody 
on days -10, -8, and -6 to B6JAF1 recipients which were graf­
ted with B10.D2 skin on day -10. In order to manipulate the an­
tigenic challenge, the residence of these first grafts was va­
ried. They were removed either at day -8, -6, or -3. The effect 
of these protocols was analyzed by regrafting the recipients 
with B10.D2 skin on day 0. As is shown in Table IX, group 4, 
pregrafting in the absence of antibody resulted in sensitiza­
tion, the magnitude of which was dependent on the time that these 
first grafts resided on their hosts. This sensitizing effect 
could be modulated by administration of alloantibody on days 0, 
2, and 4, but only if the residence of these first grafts did 
not exceed 3-4 days (group 5). In these groups, where first 
grafts were removed at days -8, or -6, the sensitizing effect 
could be prevented completely by the administration of allo­
antibody at the time of first grafting (group 6), and the sur­
vival of second grafts was prolonged in comparison with untrea­
ted controls (group 1). However, the prolongation was not grea­
ter than graft survival in those recipients which had received 
antibody alone (group 3). If in addition, antibody was also 
administered on days 0, 2, and 4 (group 7), graft survival im­
proved again but it was inferior to the standard treatment for 
the induction of enhancement, the administration of alloantibo­
dy on days 0, 2, and 4 after grafting (group 2). 
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Table Vili. Effect of the separate administration of alloantigen and alloantibody in C57BL/10 recipients of 
Β10.Ό2 skin 
Group Treatment 
Timing 
(days) 
Route 
a) MST Ζ. S.D. 
Controls Complex treated 
1 
2 
3 
4 
none 
alloantibodyb) 
alloantibody 
+ DOC-extract 
alloantibody 
+ lymphocytes 
- 15 vl 
- 50 μΐ 
- 150 μΐ 
- io4 
10 
io6 
io7 
О, 2, 4 
-7, -5, -3 
-7 
-10 
-11 
i.p. 
i.p. 
i.e. 
I.V. 
i.v. 
11.3 + 1.1 
16.6 + 1.1 
11.2 + 1.1 
12.0 + 1.3 
13.1 + 1.1 
8.5 + 1.1 
9.7 + 1.1 
10.9 +1.1 
8.9 + 1.2 
8.1 + 1.0 
7.0 + 1.0 
a) i.p.: intraperitoneally, i.V.: intravenously, i.e.: intracutaneously 
b) alloantibody was always administered in doses of 0.25 ml 
c) DOC-extract was emulsified in Incomplete Freund's Adjuvant 
Table ix. The influenae of a first graft applied on day -10 on the survival of a second graft applied on day 
0, and the effects of enhancing alloantibody 
Group 
Treatment with antibody on days 
-10, -8, -6 0, 2, 4 
no 1st graft 
MST + S.D. (days) 
1st graft removed at day 
10.9 + 1.1 
17.5 + 1.1 
13.6 + 1.0 
7.6 + 1.1 
10.θ + 1.3 
14.1 + 1.1 
16.2 + 1.1 
7.1 + 1.1 
9.9 + 1.3 
13.0 + 1.1 
16.4 + 1.1 
<Ί 
a) 
,a) 
9.6 + 1.1 
9.7 + 1.2 
a) Second grafts were not healed in 
DISCUSSION 
The results decribed in this paper demonstrate that all proto-
cols which were designed to analyze the role of antigen-antibo-
dy complexes in enhancement, were inferior to the standard re-
gimen, the administration of alloantibodies at the time of graf-
ting. The possibility that the negative results with preformed 
complexes were due to the loss of H-2 antigens during isolation 
was excluded, because the antigeniticy of membranes and deter-
gent extract thereof, was demonstrated by inhibition of lympho-
cytotoxicity. Moreover, their immunogenicity was apparent from 
the sensitizing effects in prospective skin graft recipients. 
It is also unlikely that preformed complexes were inadequate due 
to their composition, because various ag:ab ratio's were ana-
lyzed. However, it cannot be excluded that due to their size, 
which was not investigated, preformed complexes were readily 
removed from the circulation by phagocytosis. This may particu-
larly apply for complexed membranes. As a consequence, antibody 
within such a complex would be removed as well, and this may ex-
plain why complexed membranes injected i.V.,were less efficient 
than the corresponding amount of antibody alone. 
Therefore, it was analyzed whether the separate administration 
of antigen and antibody, and putative complex formation in vivo, 
could induce immunosuppression. Because antibody alone induced 
significant enhancement when injected at the time of grafting, 
pretreatment protocols were adopted in these experiments. The 
data demonstrate however, that both with DOC-extract, lymphocy-
tes, and a skin graft as sources of antigen, the combined treat-
ment was inferior to antibody alone. 
Analysis of the survival of second grafts on recipients pre-
treated with a first graft revealed that this had resulted in 
senzitization. Nevertheless, administration of enhancing anti-
body during second grafting was able to modulate the destruc-
tive effects of the existing effector cells. This so-called ef-
ferent blockade was, among others, initially proposed to explain 
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enhancement (3). However, the protective effects reported here 
were only apparent if the antigenic challenge with the first 
graft was short. No effect of antibody was demonstrated if first 
grafts resided for longer than 4 days on their recipients. Si-
milar results were recently obtained by others. Transfer of im-
mune spleen cells to skin grafted mice resulted in accelerated 
rejection, and the administration of enhancing alloantibody 
could only partially abrogate this effect (17). As demonstrated 
here, and by others (18), enhancing antibody only suppresses the 
primary immune response and it is ineffective in sensitized re-
cipients. This indicates that, although an interference with 
effector cells may occur to some extend, it cannot fully explain 
enhancement. 
Our data show that it is more likely that antibody interferes 
with the induction of immunity, because the sensitizing effect 
of first grafts could be abrogated by the simultaneous admini-
stration of alloantibody. The dose of antigen was clearly im-
portant, because with greater numbers of lymphocytes, or a lon-
ger residence of first grafts, sensitizing effects re-appeared. 
This explains, at least in part, some of the negative results 
with antigen-antibody complexes. On the other hand, in several 
experiments graft survival was not influenced at all, or equi-
valent to the effect of antibody alone. This may indicate that 
antibody merely acted by the removal of antigen and thereby re-
duced the antigenic stimulus (3, 19). This possibility cannot 
be excluded on the basis of our data, but evidence exists that 
also this mechanism cannot fully explain enhancement (20) . The 
most striking evidence which argues against this mechanism, is 
the recent demonstration of tumor enhancement by anti-TNP anti-
body and TNP-conjugated alloantigen, because the anti-TNP anti-
body cannot interfere with the graft itself (12) . Instead, this 
argues strongly for the role of antigen-antibody complexes, and 
it has been proposed that antigen-antibody complexes opsonize 
antigen-reactive cells, which may result in the elimination of 
these lymphocytes by phagocytosis (22). That in our hands, an-
tigen-antibody complexes were ineffective, may be caused by the 
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pretreatment protocols that were used. It has been demonstrated 
in the enhancement of rat kidneys (23-25), and mouse skin (26, 
27), that enhancing antibody induced a delay in the induction 
of cell-mediated immunity, but once re-appeared, that the 
strength of the response is not decreased. This suggests that 
the effect of antigen-antibody complexes on antigen-reactive 
cells occurs locally and may be short lasting. Opsonization may 
result in a reduction of peripheral lymphocytes, but due to the 
recruitment of cells from secondary lymphoid organs, this effect 
may only be temporal. This may explain why pretreatment was in­
effective, whereas, as reported by others, the use of antigen-
antibody complexes at the time of grafting induced significant 
enhancement (7-9,21). 
Our results with antigen pretreatment showed that the immunoge-
nicity of МНС-antigens depended on their form, the route of ad­
ministration, and the timing, and this is in agreement with re­
sults from others (28). Nevertheless, administration of donor 
antigen resulted in accelerated rejection, rather than enhance­
ment. Recently, the specific suppression of DTH to alloantigens 
was reported, using preimmunization with irradiated allogeneic 
cells (29). When we applied this system to induce suppression 
for grafted skin however, accelerated rejection resulted in all 
experiments (unpublished observations). Similarly, accelerated 
rejection of thyroid allografts has been reported in mice, that 
showed severely depressed MLC and CML activities following the 
g 
injection of 10 donor spleen cells (10). However, that the 
principle of unresponsiveness induced by antigen pretreatment 
does apply to skin grafts was recently demonstrated in our la-
boratory, using BALB/c H-2 recipients of BALB/c Bykh skin, 
pretreated with donor spleen cells (manuscript in preparation). 
As this combination only differs for the H-2L antigen, these 
results indicate that the extend of the МНС-barrier may be cri­
tically involved. 
In conclusion, we have demonstrated that the use of alloantibody 
alone, was superior to the use of donor antigen, or antigen-an-
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tibody complexes for the enhancement of mouse skin allografts, 
and that enhancing antibody operates at the induction phase of 
the immune response. The negative results with antigen-antibody 
complexes may indicate that their effect, if any, is not long-
lasting. 
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EFFECTS OF IgG AND IgM ALLOANTIBODIES IN THE ENHANCEMENT OF MOUSE SKIN 
ALLOGRAFTS AND THE RELATION WITH THEIR OPSONIZING CAPACITY IN VIVO' 
SIMON P. M. LEMS.2 WIM P. M. TAMBOER, PETER J. A. CAPEL, AND ROBERT A P. KOENE 
From the Department of Mediane Division of Nephrology Umversrty of Nijmegen, St Radboudztehenhuis Nijmegen The Netherlands 
The capacity of IgG and IgM alloantlbodles to enhance 
the survival of B10.D2 skin, grafted onto B6AF, recipi­
ents, was compared with their opsonizing capacity in 
vivo. 
IgM and IgG were purified by gel filtration on a Sephac-
ryl S-ЭОО column, using B6AF, anti-B10.D2 serum, which 
was collected 8 days after immunization. Administration 
of IgG together with rabbit С resulted In acute antibody-
mediated graft rejection (AAR), whereas IgG alone was 
able to induce enhanced graft survival. By contrast, ad­
ministration of IgM, with cytotoxic activity similar to IgG, 
and similar activity in AAR, did not result in enhancement. 
Prior incubation of s 1 CMabeled leukocytes with IgM 
failed to change their in vivo spleen/liver distribution, 
whereas with IgG antibodies a profound liver diversion 
was observed. These results show that enhancing IgG 
antibodies are opsonizing in vivo, whereas nonenhancing 
IgM antibodies are not. They support the recently pro­
posed hypothesis that opsonization of antigen-reactive 
cells (ARCO) is involved in the induction of enhancement. 
Passive administration ol altoantibodies to recipients of an allo­
graft can influence graft survival m several ways On the one hand. 
binding of antibodies to allografts may lead to hyperacute comple­
ment- (C) dependent graft rejection (1) In the mouse having an 
inefficient С system this phenomenon can only be demonstrated 
if an effective heterologous С source is administered simultane­
ously with alloantibody (2. 3) On the other hand, immune respon­
siveness to the graft antigens can be manipulated by alloantibod-
Recetved for publication February 10 19Θ1 
Accepted lor publication April 30 1981 
The costs of риЫісаІюг of this article were defrayed in pari by the payment 
ol page charges This article must therefore be hereby marked advertisement in 
accordance with 1 θ U Ь С Section 1734 solely to indicate this fact 
1
 This work was supported by grants Irom the Netherlands Foundation lor 
Medical Research (FUNGO) and Irom the Netherlands Kidney Foundation 
г
 Reprint requests should be addressed to S Ρ M Lems Division of Nephrol­
ogy St Radboudziekenhuis 6500 HB Nijmegen The Netherlands 
tes, and the phenomenon of immunologic enhancement of allo­
grafts is an example of the suppression of the immune response 
(1.4) 
We have shown previously thai enhancement is an Fc-dependent 
phenomenon Highly purified F(ab')z fragments of altoantibodies 
were unable to prolong skin allograft survival or to enhance tumor 
growth in Ihe same mouse model (5. 6) As a first approach to the 
investigation of the nature of this Fc dependence, we have com­
pared the effects of IgG with those of IgM alloantibodies The role 
ot IgM m the induction of enhancement has been studied mainly in 
tumor models In various reports it was shown that IgM alloanti­
bodies were able to induce enhanced tumor growth with either less 
efficiency than IgG (7) or with comparable effectiveness (8-10) 
However, using similar models, other authors were unable to detect 
enhancing effects mediated by IgM (11-15), and comparable 
failures were reported with Kidney transplants in the rat (16-18) 
The controversy extends to systems where administration of IgG 
antibodies induces specific suppression of antibody formation. 
since here also ineffectiveness (19) as well as delimte suppressive 
activity (20) of IgM was demonstrated 
The uncertainty about the role of difterenl immunoglobulin 
classes in the induction ol antibody-mediated immune suppression 
is related to unanswered questions concerning the mechanism of 
this phenomenon Recently, it was proposed that the induction of 
enhancement might be the result of the phagocytosis of specific 
antigen-reactive cells, which had bound immune complexes con­
sisting of released graft antigen and administered alloantibody 
(21) This phenomenon has been called antigen-reactive cell op­
sonization (ARCO) 3 
We have therefore compared the effects of IgG and IgM altoan­
tibodies in the enhancement of skin allografts in relation to their 
opsonizing capacity in the same mouse model The induction of 
acute antibody-mediated rejection (AAR) by these antibodies was 
used as a probe for their in vivo reactivity It will be shown that IgM 
antibodies were neither enhancing nor able to opsonize, in contrast 
3
 Abbreviations used in this paper AAR acute antibody-mediated rejection 
ADCC antibody-dependent cell-mediated cytotoxicity ALS anti-lymphocyte se­
rum, ARC anligen-reactivo calls ARCO antigen-reactive cell opsonization CTU 
cytotoxic unit L I localization index B10AF, (A/HeJ x C57BL/10)F, B6AF,, 
(A/HeJ x C57BL/6Rij)F, 
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to IgG anl ibodies, which were active in enhancement as well as m 
opsonization 
M A T E R I A L S A N D M E T H O D S 
Animals I n b r e d s t r a i n s o l B I O D 2 o l d S r B 1 0 D 2 n e w S n B I O B R A / 
H e J a n d C 5 7 B L / 1 0 m i c e w e r e o r i g i n a l l y o b t a i n e d f r o m The J a c k s o n 
L a b o r a t o r y ( B a r H a r b o r M E ) a n d C 5 7 B L / 6 R i j m i c e f r o m tho R a d i o b i o l o g i c a l 
I n s t i t u t e R i j s w i j k The N e t h e r l a n d s B 1 0 A F a n d B 6 A F h y b r i d s w e r e m a t -
i n g s o f A / H e J a n d C 5 7 B L / 1 0 a n d o f A / H e J a n d C 5 7 B L / 6 R i | r e s p e c t i v e l y 
B 6 A F h y b r i d s w e r e u s e d a s s k m - g r a f t r e c i p i e n t s w h e r e a s B l OAF m i c e 
w e r e u s e d in l iver d i v e r s i o n e x p e r i m e n t s T h e n o n - H 2 d i M e r e n c e s (H 9) 
b e t w e e n C 5 7 B L / 1 0 a n d C 5 7 B L / 6 h a v e n o e f f e c t o n i m m u n e r e s p o n s i v e ­
n e s s a s m e a s u r e d b y s k i n - g r a f t r e j e c t i o n ( 2 2 ) 
Antisera В б А Г , a n t i - B I O D 2 s e r u m w a s o b t a i n e d b y a n ι ρ i n j e c t i o n of 
a s u s p e n s i o n o l 5 x 1 0 B 1 0 D 2 l y m p h o c y t e s in a d d i t i o n to i n j e c t i o n o l a 
s i m i l a r n u m b e r o t l y m p h o c y t e s e m u l s i f i e d in c o m p l e t e F r e u n d s a d j u v a n t 
( C F A D i f c o D e t r o i t M l ) P e a k t i t e r s o l I g M a n t i b o d y a c t i v i t y w e r e o b t a i n e d 
θ d a y s a f t e r m m u n z a t i o n a s j u d g e d b y s u c r o s e d e n s i t y g r a d i e n t c e n t n l L -
g a t i o n ( 2 3 ) a n d c y t o t o x i c i t y a s s a y P o o l e d s e r a w e r e t r e a t e d w i t h ( N N 4 ) ^ 5 0 * 
at 5 0 % s a t u r a t i o n a n d t h e p r e c i p i t a t e d p r o t e i r s s o l u b i l i z e d in P B S w e r e 
s t e r i l i z e d by p a s s a g e t h r o u g h a s e r i e s o l m e m b r a n e t i l l e r s ( S c h l e i c h e r a n d 
S c h u i l D a s s e l W e s t G e r m a n y ) w i t h d e c r e a s i n g p o r e s i z e s r a n g m q ( r e m θ 
μ t o 0 2 μ 
B 6 A F a n t i - B I O D 2 d s c i t e s f l u i d w a s o b t a i n e d b y w e e k l y ι ρ i n j e c t i o n s of 
a s u s p e n s i o n o l 5 x 1 0 B I O D 2 l y m p h o c y l e s in C F A a s d e s c r i b e d e a r l i e r 
( 5 ) A n t i - l y m p h o c y t e s e r u m ( A L S ) w a s r a i s e d in g o a t s by a s u b c u t a n e o u s 
i n j e c t i o n o l 5 χ 1 0 H C 5 7 B L 6Ri) l y m p h o c y t e s s u s p e n d e d m C F A l o l l o w e d 
b y 2 w e e k l y ι ν i n j e c t i o n s o l 5 χ 1 0 h C 5 7 B L / 6 R i j l y m p h o c y t e s in s a l i n e 
A n t i - m o u s e e r y t h r o c y t e a n t i b o d i e s w e r e r e m o v e d I r o m the A L S by a d s o r p ­
t ion w i l h C 5 7 B L / 6 R I J e r y t h r o c y t e s A n t i s e r a u s e d in vivo w e r e h e a t - m a c t i -
v a t e d at 5 6 J C t o r 3 0 m i r 
isolation of IgM and IgG S e p a r a t i o n of I g M t r o m I g G w a s a c h i e v e d u s i n g 
g e l M t r a f i o n o l 4 - m l a l i q u o t e o n а Э χ 1 0 0 e n c o l u m n c o n t a i n i n g S e p h a c r y l 
S - 3 0 0 s u p e r f i n e ( P h a r m a c i a U p p s a l a S w e d e n ) E l u t e d t r a c t i o n s w e r e 
a n a l y z e d tor I g M I g A a n d I g G b y m e a n s o l r o c k e t e l e c t r o p h o r e s i s a g a nst 
c l a s s - s p e c i f i c a n t i - m o u s e a n t i s e r a ( M e l o y L a b s S p r i n g f i e l d V A ) I g M - a n d 
I g G - c o P t a m i n g f r a c t i o n s w e r e p o o l e d a n d c o n c e n t r a t e d t o t h e i r o r i g i n a l 
v o l u m e s u s i n g Y M - 1 0 a n d X M 5C i n t e r s r e s p e c f i ^ p l y ( A m i c o n L e x i n g t o n 
M A ) C r o s s - c o n t a m i n a t i o n w a s a s s e s s e d b y r a d i a l i m m u n o d i l f u s i o n a n d t h e 
p u n l i e d I g M f r a c t i o n s w e r e r s c h r o m a t o g r a p h e d at l e a s l o n c e o n th e s a m e 
c o l u m n 
C y f o f o x f C f y a s s a y T h e m viro c y t o t o x i c a c t i v i t y o l a l l o a n t i s e r a w a s 
d e t e r m i n e d b y t r y p a n b l u e e x c l u s i o n w i t h B 1 0 D 2 B I O BR or B 1 0 A F 
s p l e e n c e l l s I r e e d o l e r y t h r o c y t e s b y t r c a t m e r t w i t h N H X I U s i n g m i c r o l i t e r 
p l a t e s ( G r e m e r N ü r t i n g e n W e s t G e r m a n y ) 2 5 μί o l a ce l l s u s p e n s i o n ( 5 
χ l O V m l ) w e r e i n c u b a t e d w i t h 2 5 μΐ of a d i l u t i o n s e n e s of a l l o a n l i b o d y in 
H a n k s b a l a n c e d sa l t s o l u t i o n a n d 2 5 μΙ d i l u t e d (1 4) raDbi t s e r u m a s the С 
s o u r c e for 3 0 m m a l ЗТ^С T h e r a b b i t s e r a w e r e p r e s e l e c t e d a n d o n l y 
t h o s e s e r a that l y s e d 1 0 % o r l e s s o l t h e m o u s e l y m p h o c y t e s in t h e a b s e n c e 
o l a l l o a n l i b o d y w e r e u s e d 
Live'diversion of antibody coated spleen cells B I O D 2 s p i e e n c e l l s (1 5 
χ IO*1 ml) I r e e d of e r y t h r o c y t e s b y t r e a t m e n t w i t h N H i C l w e r e i n c u b a t e d 
w i t h 7 5 μΟι o I N a 1 1 C r O * ( T h e R a d i o c h e m i c a l C e n t r e A m e r s h a m U K s p e c 
a c t 1 0 0 t o 3 5 0 /»Ci/VgCr) f o r 4 5 m m at 37ύ0 m H a n k s b a l a n c e d salt 
s o l u t i o n s u p p l e m e n t e d w i t h 0 1 % B S A A f t e r i n c u b a t i o n t h e c e l l s w e ' e 
w a s h e d t w i c e in t h e c o l d a n d t h e r e a f t e r d e a d c e l l s w e r e r e m o v e d a s 
d e s c r i b e d by H u d s o n a n d H a y ( 2 4 ) A l i q u o t s o l 1 0 " c e l l s •'O 1 m l w e r e t h e n 
i n c u b a t e d w i t h v a r y i n g c o n c e n t r a t i o n s o l a n t i - B 1 0 D 2 a n t i b o d y f r a c t i o n s lor 
3 0 m m a l r o o m t e m p e r a t u r e w a s h e d o n c e a n d i n j e c t e d ι ν i n t o B I O D 2 
o l d o r B l O A F m i c e I r a d d i t i o n to n o r m a l B 1 0 A F , r e c i p i e n t s B 1 0 A F n i c e 
that h a d b e e n g r a f t e d w i t h В 1 0 D 2 s k i n 4 d a y s e a r l i e r w e r e u s e d A f t e r 3 h r 
r e c i p i e n t m i c e w e r e k i l l e d a n d l i v e r s a n d s p l e e n s w e r e r e m o v e d for g a m m a 
c o u n t i n g 
In c o n t r o l e x p e r i m e n t s l a b e l e d B l O A F s p l e e n c e l l s i n c u b a t e d w i t h 
s i m i l a r a m o u n t s o l a n t i - B 1 0 D 2 a n t i b o d y a n d a l s o w i t h a r a r t i A H e J 
s e r u m a s a p o s i t i v e c o n t r o l w e r e u s e d T h e p r e s e n c e o( s p e c i f i c a n t i b o d y 
o n t h e c e l l s t o b e i n j e c t e d w a s a n a l y z e d w i t h t h e c y t o t o x i c a s s a y S a m p l e s 
w e r e i n c u b a t e d w i t h d i l u t e d (1 4) r a b b i t s e r u m for 3 0 m m at 3 7 ~ C a n d lys is 
w a s e s t i m a t e d b y t r y p a n b l u e i n c l u s i o n a s w e l l a s b y s p e c i f i c * C r - r e l e a s e 
D o s e s of a n t i b o d y a r e e x p r e s s e d m c y t o t o x i c u n i t s ( C T U ) O n e C T U is 
d e f i n e d a s the a m o u n t o l a l l o a n t i b o d i e s l y s i n g 5 0 % o l 1 0 e c e l l s to b e 
i n j e c t e d R e s u l t s of t h e o p s o n i z a t i o n e x p e r i m e n t s a r e e x p r e s s e d a s th e 
p e r c e n t a g e of i n j e c t e d c o u r t s p r e s e n t in the s p l e e n a n d in th e l iver 
L o c a l i z a t i o n i n d i c e s ( L I ) w e r e c a l c u l a t e d b y d i v i d i n g t h e m e a n l i v e r , s p l e e n 
r a t i o of a n t i b o d y - t r e a t e d c e l l s by the m e a n l i v e r / s p l e e n r a t i o of u n t r e a t e d 
c e l l s a s d e s c r i b e d b y H u t c h i n s o n ( 2 1 ) 
Skin grafting T r a n s p l a n t a t i o n of B 1 0 D 2 a n d B I O B R ta i l s k i n o n t o 
B 6 A F , r e c i p i e n t s w a s e a r n e d o u t a s d e s c r i b e d e a r n e r (3) 
Enhancement of allografts R e c i p i e n t s o l B I O D 2 a n d B I O B R s k i n g r a f t s 
w e r e i n j e c t e d ι ρ w i t h e i t h e r 0 2 5 m s e r u m o r t h e I g M o r I g G f r a c t i o n s 
t h e r e o f o n d a y s 0 2 a n d 4 a f t e r g r a f t i n g 
AAR A c u t e r e j e c t i o n o l w e l l - e s t a b l i s h e d g r a f t s o n i m m u n o s u p p r p s s e d 
r e c i p i e n t s w a s i n d u c e d by ι ν i n j e c t i o n o l a l l o a r t i b o d y t o g e t h e r w i t h 0 2 5 
ml r a b b i t С at d a y 7 a l t e r g r a f t i n g T h e r e c i p i e n t s w e r e i m m u n o s u p p r e s s e d 
b y ι ρ i n j e c t i o n s ot 0 2 5 n i A L S o n d a y s 0 2 a n d 4 a l t e r g r a f t i n g """ie 
r a b b i t s e r u m u s e d a s С s o u r c e w a s p r e s e l e c t e d a n d h a d n o c y t o t o x i c e f f e c t 
o n m o u s e l y m p h o c y t e s 'Л vitro 
R E S U L T S 
Purification of IgM and IgG The IgM Irachon from anti-BIO D2 
serum col lected θ days after immunization was prepared using salt 
precipitat ion and gel f i ltration Of the gel fi ltration media tested 
Sephacryl S-300 superfine gave the best results Initial at lempts 
using Sephadex G-200 resul led m a suboptimal separation of IgM 
trom IgA and IgG whereas the use of Bio-gel A 0 5 M resul led m 
considerable losses ot IgM activity The loss ot IgM activity was 
noi due lo its inherenl instability as reported by others (13) Various 
treatments demonslrated that IgM was as stable as IgG (Table I) 
However it has been reported that IgM interacts nonspecif ical ly 
with l ipoproteins that are adsorbed onto agarose matrices (25) 
Therefore we removed l ipoprotein with CaC l ï /dex t ran sulfate (25) 
before gel f i l trat ion, but al though this procedure improved the IgM 
recovery the results were sLill inferior to direct appl icat ion of the 
Sephacryl column (Table I) 
IgM containing fract ions from a 1st run were concentrated to 
the original volume and rechromatographed once The 19S mate-
rial f rom the 2nd runs was pooled and concentrated to roughly the 
same IgM concentrat ion as was present in the original serum 
Overall IgM recovery was SS 'V with one-fourth of the cytotoxic i ty 
of the original serum (Table II) Prolem eluted m the 7S region of 
the first gel f i l tration runs was used as a source of IgG Pooled 
tract ions were concentra led and character ized by radial immuno-
di l tusion as shown in Table II Overall IgG recovery was 8 3 % , wi th 
one- lourth of the cytotoxic i ty present in the original serum 
AAR of skin allografts The m vivo antigen binding capaci ty of 
the various preparat ions was tested by their ability to induce AAR 
Graded amounts of ant ibody together with 0 25 ml rabbit С were 
administered ι ν to immunosuppressed B6AF recipients of 
B 1 0 0 2 skin on day 7 after graft ing The resulls given m Table III 
show that similar amounts o l IgG or tgM antibody, based on their 
lymphocytotoxic titers in vitro, were almosl equally effective in the 
induction o l complete necrosis of the grafts within 4Θ to 7 2 hr 
Enhancement of skin allografts Having d e m o n s l r a l e d the in vivo 
activity of the immune serum and of the purif ied f a c t i o n s in AAR 
the ability to induce passive enhancement was tesled The results 
shown in Table IV demonstrate that administrat ion of early unfrac-
l ionated anl i-BIO 0 2 serum resulted in a signif icant prolongat ion 
ol Ihe survival ot B10 0 2 skin However this enhanced survival 
T A B L E I 
Recovery of IgM antibody activity after various manipulations 
Trcalmp-I Recovery* 
P r p c i p i t a i i o n with ( N H i b S O * 
Incubat ion at 2$rC (3 w k ) 
Freezing and t h a w i r g ( 6 x ) 
Gel Nitration on Bio-Gel A-0 5 M 
Bio-Gel A-0 5 M after removal of l ipoprotein 
Gel f i l trat ion on S e p h a c r y l 5 - 3 0 0 
1 0 0 
1 0 0 
" L y m p h o c y t o t o x i c activ i ty of Ihe 1 9 S fract ion after s u c r o s e density gradient 
c e n t n l u g a t i o n 
In vitro properties of B6AF anti-B 10 02 ailoantisera and ot the IgG and IgM 
fractions 
\QM 
Согсрлча'юп (mg/ml)* 
IgG' IgG?"· 
H y p e n m m u r e asc i tes 
Day θ serum 
IgM f ract ion 
IgG f r a c t i o n 
1 1 0 0 0 
1 1 2 8 
1 3 2 
N D 
0 72 
0 6 4 
«-,0 0 2 ' 
5 05 
2 71 
С 005 
3Θ2 
4 11 
2 Э 5 
0 0 1 2 
4 60 
* Determined by radial immunodif fLSion 
' IgGSa + l g G 2 b 
' N D not d o n e 
" Less than the d e t e c t i o n level of IgM 
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TABLE III 
Activity of 86AF, anti-BW 02 antiserum and the IgG and IgM preparation m 
acute antibody-mediated rejection m B6AF recipients of BW 02 skin grafts 
(AAR) 
Treatment* Volume 
ml 
0 6 
0 75 
0 125 
0 25 
0 5 
0 125 
0 25 
0 5 
AAR 
2/5* 
5/5 
0/5 
2/5 
5/5 
2/4 
4/5 
5/5 
a control, BIOAF1 spleen cells were used after incubation with the 
same amounts of anti-B10D2 antibody and with an anti-A/HeJ 
serum The results in grafted recipients, given in Figure 2. show 
the specific and profound opsonizing capacity of IgG antibodies 
Moreover, the magnitude of the observed liver diversion was similar 
to the effects seen in B10D2 old recipients By contrast. IgM 
antibodies were ineffective at 2 5 and 12 5 CTU, whereas the liver 
diversion seen with the highest amount tested could not be discrim­
inated from the nonspecific effect displayed on B10AF, control 
cells No differences were observed between normal and grafted 
recipients, and therefore only the results m the latter group are 
shown 
When the samples used for injection were incubated with rabbit 
C, B10 D2 cells incubated with IgG or with IgM were I y eed com-
* AAR is evoked by administration or alloantibody together with 0 25 ml rabbit 
С to tmmunosuppressed recipients on day 7 after grafting 
D
 Number of recipients showing complete necrosis of the graft within 48 lo 72 
hr divided by the tola! number mjecled 
TABLE IV 
Passive enhancement by B6AF, anti-BtO 02 alloantisera and the IgG and IgM 
preparations m 86AF, recipients of θ f 0 02 skin grafts 
Treatmen!' 
None 
Anli-CFA sefum* 
B6AF, anti-BIO D2 
- Day 8 serum 
- loG fraclion 
- IgM Ігасіюп 
- Hypenmmuno asures 
No Récit*. 
елгз 
10 
7 
9 
9 
10 
10 
MST ± SD° 
103 ± 1 1 
100 ± 1 1 
145 I 1 0 
143 ± 1 1 
103 ± 1 1 
20 1 ± 1 1 
P' 
N S · 
<0 0025 
<0 01 
N S 
<0 0005 
" 0 25 ml administered on days 0, 2 and 4 after grafting 
" Median survival time ± SO 
c
 Level of significance (Student s t-tesl) 
" Coltecled from B6AF, mice 8 days after Injecllon of complete Freund s 
adjuvant 
" Not significant 
was caused exclusively by the IgG antibodies present in this serum 
IgM alloantibodies, effective in AAR, were completely devoid of 
enhancing activity, whereas the isolated IgG fraction demonstrated 
similar enhancement as the serum from which it originated The 
anti-B10 D2 serum and the IgG and IgM fractions thereof had no 
effect on the survival of BIO BR control skin grafts 
L/ г diversion of antibody-coated spleen cells According to the 
ARCO hypothesis, opsonization of antigen-reactive cells (ARC) is 
involved m the induction of enhancement Therefore, we analyzed 
whether the different effects of IgG and IgM in enhancement could 
be correlated with their opsonizing capacity m vivo Spleen cells of 
B10 02 donor mice, labeled in vitro with ^'Cr, were incubated with 
anti-B10D2 antibody and injected ι ν info recipient mice To 
exclude the possibility that C-mduced lysis of these coated cells 
could be responsible for any observed liver diversion, the lytic 
activity of mouse С on these cells was investigated first IgG-coated 
spleen cells (10s) were incubated m vitro with either 25 μΙ diluted 
(1 4) rabbit С or with 200 μ\ undiluted mouse С For this purpose, 
freshly drawn blood from male C57BL/10 mice was used, which 
has a relatively high lytic activity on antibody-coated SRBC (26) 
Using rabbit С complete cell lysis was observed, in contrast to 
mouse C. which had no lytic activity at all (data not shown) As a 
2nd approach, spleen/liver localization of antibody-coated cells 
was investigated using congemtally C-5-delicient Θ10 02 old mice 
The results given in Figure 1 demonstrate the opsonizing capac­
ity of IgG antibodies m the absence ol lytic С activity Using 
suspensions of viable cells without prior incubation with antibody, 
the percentage of cells moving to the spleen exceeded the number 
of cells sequestered in the liver Cells incubated with IgG. however, 
were diverted away from the spleen, with a simultaneous increased 
localization m the liver m a dose-dependent manner 
The opsonizing effect of IgG was then compared with IgM using 
BlOAF, recipients In order to mimic the events occurring in the 
enhancement protocol as closely as possible. BlOAF, mice were 
used, which had been grafted with B10 02 skin 4 days before the 
diversion experiments, in addition to normal BlOAF, recipients As 
125 63 5 
ant ibody! CTU) 
Figurai Dose-dependent liver diversion of B10 02 splenic leukocytes 
coated in vitro with IgG aHoantlbody in BIO D2 old (C5-de<<cient) recipients The 
means ± SD of the counts recovered m spleen (A 4) and in liver ( · — · ) of 
at least 3 mice per group are expressed as the percentage of the lotal dose 
injected 
localization m d m -
2 5 12 5 37 5 6 2 5 
anubody (CTU) 
Figure 2 Localizaron indices m grafted BlOAF, recipients of BlO D2 leu­
kocytes incubated wilh anti-B 10 02 IgG ( · · ) and IgM (A A) alloantibody 
and ol BlOAF, leukocytes incubated with anti-Bl0 02 IgG (O—C) and IgM 
(Λ—Δ) Each point represents the means ± SO ol al least 3 recipients m 2 
separate eitpenments 
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pletely. indicating the successful coating of these cells B10AF, 
control cells that had been incubated with antt-B10 D2 IgG or IgM 
were not lysed under these conditions Only after incubation of 
these cells with the relevant anti-A/HeJ serum could strong liver 
diversion and lysis with rabbit С in vitro be demonstrated 
DISCUSSION 
In earlier studies from our laboratory, the enhancing capacity of 
IgG alleanti bodies was established (27) Dose-response curves 
indicated thai 27 ug lgG2 with a cytotoxic titer of 1 512 were able 
to induce significant prolongation of skin graft survival in the mouse 
model used Similar studies demonstrated (hat IgG 1 alloanlibodies 
were also enhancing although less effective than lgG2 
The enhancing capacity of IgG antibodies is confirmed m this 
sludy By contrast, IgM antibodies failed lo induce enhanced graft 
survival To exclude that this result was due to inefficient antigen 
binding, the activity of IgM was tested /л vitro and in vivo Antigen 
binding and activation of rabbit С in vitro was demonstrated by 
lymphocytotoxicity Interaction with the graft antigens m vivo was 
shown by the observation that m terms of cytotoxic units, the IgM 
preparation was almost as effective m the induction ol AAR as the 
IgG preparation The activity of IgM in AAR cannot be the result of 
contaminating IgG The IgM preparation contained 12 дд/ті of 
lgG2 and 5 fig/ml of IgGl In the induction of AAR, using 0 5 ml, 
these contaminations amounted to 6 да lgG2 and 2 5 μg IgGl, 
whereas the threshold dose of lgG2 to induce AAR is 40 дд, and 
IgGl is ineffective in AAR m doses up to 2000 μς (27) 
For the study of the opsonizing capacity of the IgG and IgM 
antibodies, a model was chosen consisting of the in vivo liver 
diversion, in normal and in grafted recipients, of lymphocytes 
labeled with 5 ,Cr and coated with antibody in vitro By using an in 
vitro procedure, we were able to determine by means ol a lympho-
cytotoxic assay whether the lymphocytes were indeed coated with 
antibody before their injection Moreover, amounts of antibody 
could be used exceeding those attainable by administration in vivo 
In addition to normal recipients, grafted animals were used, in 
order lo study opsonization m the natural physiologic environment 
in which enhancement takes place No differences were observed 
between grafted and normal recipients, and the results demon­
strate that in contrast to IgG, IgM has no opsonizing activity m vivo 
The inability ol IgM to induce enhancement is in agreement with 
results ol others, using rat kidney allografts (16-18) and tumors 
(11-15). and it supports our findings that the antibody response of 
nude mice to allogeneic and xenogeneic skin grafts is abrogated 
by IgG. but not by 19S IgM antibodies (28) The results demon­
strate also thai lor the production of enhancing antibodies, hyper-
immumzation is nol a prerequisite, as suggested by Stuart ei at 
(29), but lhal the amount of specific IgG antibody present in the 
serum determines the enhancing capacity of early immune sera 
That IgM antibodies are not enhancing reinforces the concept 
that masking of antigenic determinants is not an adequate expla­
nation for enhancement, since both nonenhancing IgM antibodies 
and enhancing IgG antibodies bind to the target antigens, as 
judged by their ability to induce AAR The possibility that the IgG 
and IgM fractions nevertheless have different specificities is not 
very likely, because IgM and IgG were isolated during a primary 
immune response m which the specificities of IgM antibody pre­
cede those of IgG That IgM antibodies are neither enhancing nor 
opsonizing extenda previous findings that showed that enhance­
ment is Fc-dependent (5, 6, 30) 
It was recently proposed by Hutchinson (21) that passively 
administered antibodies could form immune complexes with cell 
bound or soluble antigens released from the graft Recognition and 
binding by ARC, of these complexes in antigen excess could then 
result in ARC-macttvation by phagocytosis, as was demonstrated 
in rats bearing passively enhanced renal allografts (31 32) and 
also in mice (33) Nevertheless, mactivation of ARC does not 
necessarily occur via opsonization alone, but other effector mech­
anisms like antibody-dependent cell-mediated cytoloxicity (ADCC) 
or C-mediated lysis could be involved However, the liver diversion 
we observed in mice deficient in lytic С was of comparable mag­
nitude m Bl OAF mice Furthermore the fact that in mice AAR can 
only be induced after administration of heterologous C. and the 
observation that, m accordance with reports from others (34, 35). 
antibody-coated cells were not lysed by fresh mouse serum indi­
cate that C-mediated lysis is not likely to occur in vivo 
Recent observations suggest that in mice IgM antibodies are 
able to mediate ADCC (36-39) И ADCC is involved in ARC mac­
tivation. IgM antibodies should be able to induce enhancement by 
this route Therefore the finding that IgM antibodies do not induce 
enhancement argues against ADCC as an effector mechanism for 
the mactivation of ARC 
From a teleologie point of view, il seems most rewarding that 
IgM antibodies do not abrogate immune responses Instead, they 
could play a stimulatory role in Ihe humoral response, as shown by 
Henry and Jerne (40) using antibody formation against SRBC in 
the mouse, as well as m (he cellular immune response, as shown 
by Mullen ef a/ (16) using rat kidney allografts These observations 
may be related to the recent evidence for Ihe presence of Fc-μ 
receptors on T-helper cells (41 ) The immune stimulating effects ol 
IgM in these studies were most clear-cut when suboptimal antigenic 
stimuli were used, and this may explain why in our strong H-2 
incompatible skin graft model this stimulatory activity could not be 
detected 
In conclusion, we found that IgM does not induce enhancement 
and that this correlates with its lack of opsonizing activity in the 
same mouse model By contrast, enhancing IgG antibodies were 
strongly opsonizing This points to an important role for the Fc-
fragment in this form of immunosuppression These findings sup­
port the hypothesis of ARCO as an important mechanism of im­
munologic enhancement 
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Abstract 
Crafting of allogeneic or xenogeneic skin on nude mice results in a primary antibody 
response, and during this response the antibody activity switches from IgM toward IgG. We 
studied the nature of this antibody response in different nude strains (C3H nu/nu, C57B1/6 
nu/nu, B10.LP nu/nu, and В ALB/с nu/nu). At day 21 after transplantation, when anti­
body titers were falling, the transplantation of a second graft of similar donor type re­
sulted in a secondary antibody response only if the first graft had been removed before 
the appearance of IgG antibodies. Removal of the first graft after the appearance of IgG 
antibodies resulted in a nonresponsiveness of the recipient to the second graft. This sug­
gested a suppressive role of the IgG antibodies. This was supported by the finding that 
passive transfer of nude sera containing specific antibody activity of IgG class suppressed 
the primary response to a skin graft in the nude mice, whereas sera containing only IgM 
activity did not induce suppression. We conclude that, in nude mice, an allograft or 
xenograft induces a primary antibody response that switches from IgM toward IgG, and 
that the concomitant presence of antigen and IgG antibodies results in the induction of 
specific unresponsiveness. 
Introduction 
Congenitally athymic nude mice accept allografts and xenografts permanently 
(12,13). The absence of graft rejection results from the lack of cytotoxic Τ cells 
and not from the absence of a humoral response, because nude mice generate 
cytotoxic antibodies against allogeneic and xenogeneic skin grafts (4,7,13). 
Although the antibody is formed in concentrations sufficient to cause rejection 
• To whom correspondence should be addressed. 
© 1982 Gustav Fischer New York, Inc. 
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after administration of rabbit complement (4,7), such rejection does not occur 
spontaneously in the nude mice because of the inefficiency of the mouse's own 
complement system in this type of rejection (6). 
Earlier we found that in nude mice the antibody activity against allogeneic 
and xenogeneic skin grafts switched from IgM toward IgG during the primary 
response (4). In this study we have analyzed this antibody response further, 
giving special attention to the genetic background of the recipients and the 
characteristics of the secondary response. 
Materials and Methods 
Animale. Inbred B10.D2/new Sn mice were originally obtained from the 
Jackson Laboratory (Bar Harbor, Maine) and inbred PVG/c rats from the 
Institute of Psychiatry, Bethlem Royal Hospital (Beckingham, Kent, U.K.). In 
our laboratory these strains were kept by continuous brother-sister matings. 
B10.LP nu/пи were obtained from the Radiobiological Institute T.N.O. (Rijswijk, 
The Netherlands) and C3H nu/пи, C57BL/6 nu/пи, and BALB/c nu/nu were 
obtained from Gl. Bomholdgard Ltd. (Ry, Denmark). 
% Lysis 
B10.D2Q—Bio.LPnu/nuQ 
8 12 16 20 4 8 12 16 20 
Fraction number 
Figure 2S-1. Cytotoxic activity of BIO.LP nu/пи serum after ultracentrifugation on 
sucrose gradients. Sera were taken at days 4, 8, 14, and 18 after grafting of B10.D2 
skin. 
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Skin grafts. Female tail skin was grafted onto the right dorsal flank of female 
nu/пи recipients by a modified fitted graft technique (2). Donor and recipient 
mice were between 6 and 8 weeks old. Second grafts were placed onto the left 
dorsal flank. 
Serology. On different days after transplantation nude mice were bled and 
their sera stored at — 90° C. The lymphocytotoxic activity was measured in a 
trypan blue exclusion test using rabbit serum as a complement source as previ­
ously described (3). IgM and IgG antibodies were determined after separation 
of the sera on isokinetic sucrose gradients (4). 
Results 
Primary Antibody Response 
In different strains of nude mice the primary antibody response was measured 
by a lymphocytotoxicity assay at various days after grafting of allogeneic B10.D2 
or xenogeneic PVG/c skin. As recipients of the xenografts, B10.LP nu/nu, 
C57BL/6 nu/пи, C3H nu/пи, and BALB/c nu/nu were used, whereas in the 
allogeneic models B10.D2 skin was grafted onto B10.LP nu/пи or C57BL/6 
nu/пи recipients. Analysis of the sera on sucrose gradients showed cytotoxic 
activity in the 19S as well as in the 7S peak. The 19S activity reached a maximum 
at day 8 after grafting, whereas the 7S activity was maximal around day 14. 
The response of a B10.LP nu/пи recipient of a B10.D2 skin graft given in 
Figure 25-1 is similar to the responses obtained with other donor-recipient 
combinations of which the results are summarized in Table 25-1. 
Secondary Antibody Response 
The secondary antibody response to xenogeneic PVG/c skin was studied in 
B10.LP nu/пи, C57BL/6 nu/пи, C3H nu/пи, and BALB/c nu/пи recipients by 
transplantation of a second PVG/c graft on day 21 after transplantation. The 
antibody activity was measured on days 4, 8, and 14 after regrafting. Similarly, 
the secondary response to allogeneic B10.D2 skin was studied in B10.LP nu/nu 
Table 25-1. Antibody response in nude mice 
Donor 
PVG/c 
PVG/c 
PVG/c 
PVG/c 
B10.D2 
B10.D2 
Recipient 
B10.LP nu/nu 
BALB/c nu/nu 
C57BL/6 nu/nu 
C3H nu/nu 
B10.LP nu/nu 
C57BL/6 nu/nu 
titer 
cytotoxic 
1/256 
1/64 
1/512 
1/64 
1/256 
1/128 
Cytotoxic 
Day 4 
19s 
+ 
+ 
+ 
+ 
+ 
7s 
^ 
— 
— 
— 
— 
activity at : ' 
Day 8 
19s 7s 
+ + ++ 
++ + 
+ + + 
+ + + 
+ ± 
Day 14 
19s 
+ 
+ 
+ 
+ 
+ Not done 
7s 
+ + 
+ + 
+ + 
++ 
+ 
Day 21 
19s 7s 
+ ++' 
+ + 
± + 
- + 
± ± 
* Activity in 19s or 7s fraction after separation on sucrose gradients. 
»Percentage lysis: < 10%, — ; 10-25%, ± ; 25-90%, + ; >90%, + + . 
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(cytotoxic titer) 
256 
64 
16 
PVG/cÇ — Cs7BLe nu/nu Ç 
primary respons« 
secondary response 
β 12 16 20 24 28 32 36 
Days after grafting 
Figure 25-2. Primary and secondary antibody response of C57BL/6 nu/nu mice 
after transplantation of a PVC/c skin and regrafting of a second skin at day 21. 
and C57BL/6 nu/пи recipients. In none of the cases did antibody activity exceed 
the residual activity still present after the first transplantation. Regrafting with 
a third-party graft resulted in a normal response. An example of the absence of 
the secondary response is given in Figure 25-2. 
The absence of a secondary response might be caused by either a generalized 
immunologic incompetence of nude mice or the induction of suppression by the 
presence of antigen from the first graft during the production of immunosup­
pressive antibodies. We therefore studied how graft removal during the primary 
response influenced the secondary response. A B10.D2 skin graft was removed 
on days 8, 16, or 21 after grafting. Twenty days after removal of the graft the 
C57BL/6 nu/пи recipients were regrafted with B10.D2 skin. Eight days after re­
grafting, the animals were bled and the antibody activity was measured. The 
data given in Table 25-2 show that removal of the graft at day 8, i.e., before the 
appearance of IgG antibodies, resulted in a strong secondary response. Graft 
removal on days 16 or 2 1 , i.e., after IgG antibodies had appeared, lead to sup­
pression of this response. 
Table 25-2. Abrogation of secondary response by the presence of antigen 
(B10.D2 -» C57BL/6 nu/nu) 
Removal of first 
graft on: Regrafting on 
Secondary response at 
day 8 after regrafting 
Day 8 
Day 16 
Day 21 
Day 28 
Day 36 
Day 41 
1/512" (21)' 
0 (3) 
1/64 (3) 
0 (8) 
• Cytotoxic titer. 
" Number of animals tested. 
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Induction of Suppression by Immune Serum of Nude Mice 
We have determined the suppressive capacity of immune sera of nude mice 
to find out whether the absence of the secondary response was the result of the 
induction of unresponsiveness by antibodies. C57BL/6 nu/пи mice were grafted 
with B10.D2 or PVG/c skin. On days 8, 16, and 28 the mice were bled and 
0.25 ml of this serum was administered intraperitoneally (IP) to C57BL/6 
nu/пи recipients of B10.D2 or PVG/c skin graft immediately after grafting. The 
primary response was measured on day 8 after grafting. The results obtained 
after administration of normal C57BL/6 nu/пи serum or immune nude serum 
are given in Table 25-3. These results show that suppression of the primary 
response occurred with nude serum obtained 16 days after grafting. This sup­
pression is most likely caused by IgG antibodies and not by IgM antibodies 
because antiserum obtained at day 8 after grafting, which had a similar or even 
higher cytotoxic activity but lacked IgG activity, did not alter the alloantibody 
response. In the xenogeneic combination low amounts of IgG activity were de­
tectable at day 8, and only a slight suppression was observed with this serum. 
D i s c u s s i o n 
Allogeneic and xenogeneic skin grafts induce a primary antibody response 
in congenitally athymic nude mice. This is in agreement with the findings of 
Rygaard (12,13), who found an antibody response to xenografts. The absence 
of alloantibodies in his study is not in contrast with our findings because he 
Table 25-3. Suppression of antibody response by immune nude serum 
Treatment* 
A. PVG/c -» C57BL/6 nu/nu 
None 
Normal C57BL/6 nu/пи serum 
C57BL/6 nu/пи anti-PVG/c serum:' 
Day 8 (1/512)" 
Day 16 (1/256) 
Day 28 (1/16) 
B. B10.D2 -» C57BL/6 nu/nu 
None 
Normal C57BL/6 nu/nu serum 
C57BL/6 nu/nu anti-B10.D2 serum:' 
Day 8 (1/64)' 
Day 16 (1/64) 
Day 28 (0) 
Response at day 8, 
cytotoxic titer* 
1/512 
1/512 
1/128 
1/16 
1/512 
1/64 
1/64 
1/64 
0 
1/8 
1/64 
(5)» 
(4) 
(3) 
(4) 
(4) 
(6)» 
(6) 
(4) 
(3) 
(3) 
(4) 
* Intraperitoneal administration of 0.25 ml serum on day of transplantation. 
' Number of animals tested in parenthesis. 
' Serum obtained at day 8, 16, or 28 after grafting. 
* Cytotoxic titer of the serum. 
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only searched for antibodies at day 30 after grafting. We found that the allo-
antibody response has been extinguished by that time. 
During the primary antibody response the activity switched from IgM toward 
IgG. To exclude that this response was dependent on the genetic background of 
a particular nude strain, nude mice with different haplotypes were used as re-
cipients and in all cases IgM and IgG antibodies were formed. 
That the formation of antibodies does not result in graft rejection by nude 
mice is because of the inefficiency of the mouse complement system, as we have 
shown earlier (4,7). The finding that nude mice can evoke a primary antibody 
response to allografts and xenografts leads to the conclusion that major histo-
compatibility (MHC) antigens are T-cell independent or, alternatively, that MHC 
antigens need T-cell help, which is provided by a residual T-cell function present 
in nude mice. This T-cell help should then be located in the very low number of 
theta-positive cells which are present in nude mice (9,10). Although residual 
T-cell function cannot be completely excluded it seems more likely that MHC 
antigens can induce a T-cell-independent antibody response. In keeping with 
this hypothesis are the findings that the switch from IgM toward IgG in the 
response to T-cell-independent antigens does not depend on a T-cell function 
(1,8,11,14). 
The findings by Klein et al., (5), who found H-2 antigens being T-cell de-
pendent, are in contradiction with our results. However, in their study they 
used the absence of 2-mercaptoethanol (2-ME) -resistant antibodies as a criterion 
for the absence of IgG antibodies. This assumption is probably not completely 
valid since we have found that IgG is inactivated by 2-ME, especially at low Ig 
concentrations (3). 
In all donor-recipient combinations a secondary response was absent, although 
the mice could respond to an unrelated second graft. The inability to reject the 
graft and the occurrence of a primary antibody response results in the simul-
taneous presence of antigen and antibody, a situation that in normal mice can 
induce antibody-mediated suppression of the immune response. Two conditions 
must be fulfilled before one can decide that the absence of a secondary response 
is the result of an active suppression mechanism and is not a general property 
of nude mice: (a) The antibodies produced by nude mice must be able to induce 
suppression after passive transfer, (b) The removal of antigen before the appear-
ance of suppressive antibodies must result in the occurrence of a secondary 
response. Treatment of nude recipients with immune serum obtained from nude 
mice after grafting indeed induced suppression of the primary antibody response. 
It is likely that this suppression is only induced by IgG antibodies and not by 
IgM antibodies because serum obtained at day 8 after grafting, which had no 
detectable IgG activity when directed against an allograft or very low IgG 
activity when directed against a xenograft, induced no or only slight suppres-
sion, respectively. This was found in spite of the fact that these sera had the 
same or even higher cytotoxic titers than the suppressive IgG-containing serum 
obtained at day 16 after grafting. 
The occurrence of a secondary response after removal of the graft before the 
appearance of IgG antibodies shows that nude mice are able to mount a secondary 
response and that the absence of this response is a result of antibody-mediated 
suppression. 
We conclude that allografts and xenografts evoke a primary response in nude 
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mice. This response, including the switch toward IgG, is most likely T-cell inde­
pendent, although we cannot exclude a possible residual T-cell function being 
responsible. When concomitantly present with antigen, IgG antibodies induce 
specific unresponsiveness by which the response is abrogated. In contrast to IgG, 
IgM antibodies are unable to induce this suppression. 
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SUMMARY 
B6AF1 anti-B10.D2 ascites fluid was separated in highly puri-
fied IgGl and IgG2 alloantibodies, which were concentrated to 
yield similar specific antibody activities on the basis of two-
stage lymphocytotoxicity. Their similar specific activities were 
confirmed by flowcytometric analysis. When tested for enhance-
ment of B10.D2 skin, grafted onto B6JAF1 recipients, and for 
the opsonization of 51 Cr-labelled B10.D2 leukocytes, IgGl an-
tibodies were as effective as the IgG2 preparation. Therefore, 
IgGl and IgG2 antibodies have similar enhancing capacities.The 
close correlation with their opsonizing effect, supports the 
hypothesis that opsonization of antigen-reactive cells (ARCO) 
is involved in the induction of enhancement. 
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INTRODUCTION 
Administration of alloantibodies directed to the МНС-antigens 
of a donor graft may, on the one hand, induce prolonged graft 
survival (Immunological Enhancement), on the other, it may re­
sult in antibody-mediated graft rejection (AAR). Using skin al­
lografts in the mouse, we have demonstrated previously that, 
due to the inefficiency of the mouse complement system, AAR on­
ly occurs after the administration of an effective exogenous 
complement source (1), and that acute rejection is mediated by 
complement fixing (sub)classes of mouse Ig (2,3), with speci­
ficity for class I alloantigens (4). Therefore, strategies to 
arrive at non-destructive enhancing antibody preparations should 
be aimed at the isolation of non-complement fixing antibodies 
and/or the use of antibodies specific for class II MHC-antigens 
(4). 
Enhancement by non-complement fixing IgGl antibodies was demon­
strated in previous studies from our laboratory (2), although 
this subclass appeared to be 30-50 times less effective than 
IgG2. However, this comparison was based on the amounts of pro­
tein injected, and not on the specific antibody activity pre­
sent in both preparations. Therefore, we have now compared the 
enhancing capacity of IgGl and IgG2 alloantibodies on the ba­
sis of specific antibody activity. In addition, enhancing and 
opsonizing capacities of IgGl and IGG2 were compared because 
opsonization of antigen-reactive cells by immune complexes con­
sisting of released graft antigens and administered alloantibo-
dy, has been suggested as a mechanism for enhancement (5). This 
hypothesis implies that enhancing antibodies should have opso­
nizing capacity. 
It will be demonstrated that on the basis of specific antibody 
activity, IgGl alloantibodies were as effective as IgG2 anti­
bodies in both enhancement and opsonization. 
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MATERIALS AND METHODS 
Breeding pairs of B10.D2/Sn-new (H-2d), A/HeJ (H-2a), and C57BL/6J (H-2 ) 
were originally obtained from the Jackson Laboratory, Bar Harbor, Me. 
C57BL/Rij (H-2 ) originated from the Radiobiological Institute TNO, Rijs­
wijk, The Netherlands. (C57BL/Rij χ A/HeJ)F =B6AF1 and (C57BL/6J χ A/HeJ)F 
к 
=B6JAFl were raised in the laboratory. BALB.K (H-2 ) mice were obtained from 
Olac Ltd.Blackthorn, U.K. 
B6AF1 anti-BlO.D2 ascites fluid was obtained by weekly i.p. injections of 
7 
a suspension of 5 χ 10 B10.D2 lymphocytes in complete Freund's Adjuvant, 
as described earlier (6). Pooled ascites was heat-inactivated at 56 С for 
30 min, precipitated with (NH4)2S04 and after solubilization, sterilized by 
passage through membrane filters (Schleicher and Schüll, Dassel, West Ger-
many) with decreasing pore sizes ranging from θμ to 0.2μ. 
From this preparation, IgGl and IgG2 antibodies were Isolated by Sepharose-
Protein A chromatography (Pharmacia, Uppsala, Sweden) as described by Ey et 
al (7), and further purified by affinity chromatography on Sepharose-4B, 
coupled with (sub)class specific antisera (Meloy Labs, Springfield, VA, and 
Litton Bionetics, Kensington, MD) directed against residual contaminating 
immunoglobulins. Purified IgGl and IgG2 were sterilized by passage through 
a 0.2μ membrane filter. Ig concentrations were determined by radial immuno­
diffusion with myeloma proteins (Litton Bionetics) as a reference standard. 
Specific antibody activity was determined by two-stage lymphocytotoxicity 
and immunofluorescence. In cytotoxicity experiments, 25 μΐ B10.D2 splenic 
leukocytes (5 χ 10 /ml) were incubated with a dilution series of antibody, 
washed, incubated with anti-IgG, washed again, and incubated with rabbit 
complement (30 min, 37 С ) , in a final dilution of 1:12. Direct cytotoxicity 
of IgG2 was measured in the same assay, but omitting the anti-IgG2 reagent. 
Fluorescence was determined with an Ortho 50-H flowcytometer (Ortho Instr. 
Westwood, Mass.), using B10.D2 splenic leukocytes, and T-cells, purified as 
described by Julius et al (θ). Cells (5 χ 10 /ml) were incubated (1 hr, room 
temperature) with dilution series of antibody and, after washing, with FITC-
labelled anti-IgG in PBS supplemented with BSA (1%) and NaN3 (0.1%). Label­
led cells were fixed in 1% formaldehyde and analyzed within 3 days. Results 
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are expressed as Relative Fluorescence Intensities (RFI), which correspond 
to the fluorescence channels with peak numbers of cells, as determined from 
the histograms. As second antibodies, goat anti-IgGl or anti-IgG2 (Meloy) 
were used for cytotoxicity, and FITC-conjugated goat anti-IgGl (Meloy) or 
a mixture of FITC-labelled goat anti-IgG2a and anti-IgG2b (Nordic) for fluo-
rescence. 
Opsonization was studied using a liver diversion assay, as described pre-
viously (3). 51 Cr-labelled B10.D2 leukocytes, incubated with antibody in 
vitro, were injected i.v. into B6JAF1 mice, and after 3 hr, livers and 
spleens were removed for gamma counting. Results are expressed as Localiza-
tion Indices (L.I.), which were calculated by dividing the mean liver/spleen 
ratio of antibody-treated cells by the mean liver/spleen ratio of untreated 
cells. 
Transplantation of B10.D2 and control BALB.K tail skin onto B6JAF1 recipients 
was carried out by a modification of the "fitted graft" technique, as des-
cribed earlier (9). Enhancement was induced by i.p. injections of 0.25 ml 
antibody on days 0, 2, and 4 after grafting. Dilution series (1:5) were made 
in 10% normal B6JAF1 serum. 
RESULTS 
IgGl and IgG2 were isolated by Sepharose-Protein A chromatogra-
phy using a continuous, fully automated procedure. The column 
was charged at pH 8.2, eluted at pH 6.0 for IgGl, and thereaf-
ter at pH 2.6 for IgG2 (7). The latter fraction was neutrali-
zed immediately using a pH-stat. A total of 250 ml salt-preci-
pitated ascites was run in 5 cycles, and the pooled pH 8.2 ef-
fluents, concentrated to their original volume, were rechroma-
tographed once, again in 5 cycles. Residual IgG and other Ig 
contaminations were removed by affinity chromatography on Sepha-
rose-4B columns, coupled with (sub)class specific antisera a-
gainst impurities. In this way, highly purified IgGl and IgG2 
fractions were obtained with overall recoveries of 35% and 28% 
respectively. The preparations were concentrated to yield two-
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stage c y t o t o x i c i t y s imi lar to t h a t of the o r i g i n a l a s c i t e s 
(1:320).Their f i n a l compositions are shown in Table I . 
Table 1. Conaentrations of immunoglobulins (mg/ml) in the preparations 
Immunog JLobul i n anti-Bl0.D2 
ascites 
2.32 
1.Θ5 
1.57 
1.7Θ 
2.82 
0.67 
IgGl 
fraction 
4.11 
< o.ooib) 
< 0.001 
< 0.001 
< 0.002 
< 0.002 
IgG2 
fraction 
0.021 
4.59 
2.53 
0.056 
0.019 
< 0.002 
IgGl 
IgG2a 
IgG2b 
IgG3 
IgA 
IgM 
a) Determined by r a d i a l immunodiffusion 
b) < : l e s s than the d e t e c t i o n l i m i t in double di f fus ion 
After their concentration, the IgGl and IgG2 preparations gave 
specific and identical cytolysis curves in two-stage cytotoxi­
city (Fig.l). 
% cytolysis 
100 
ι 1 1 1 1 1 1 1 г 
10 20 40 80 160 320 640 1280 2560 
antibody dilution-1 
Figure 1. Direct c y t o t o x i c i t y of IgGl (0—0) and IgG2 (Δ—Δ) and two-stage 
c y t o t o x i c i t y of IgGl ( · — · ) and IgG2 (A—A) a n t i b o d i e s for B10.D2 
t a r g e t c e l l s . A n t i - I g G l andanti-IgG2 were used i n a l : 1 0 0 d i l u t i o n . 
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This similarity could be demonstrated in a number of experiments 
in which target cell concentrations or the amounts of anti-IgG 
antibodies varied. When tested for conventional cytotoxicity 
only IgG2 specifically lysed B10.D2 cells, with a titer of 1:160, 
whereas IgGl was negative (Fig.l). 
The similar specific activities of IgGl and IgG2 were also de­
monstrated by immunofluorescence. Incubation of B10.D2 spleen 
cells with diluted (1:80) IgGl or IgG2 resulted in identical 
fluorescence histograms, showing a high-intensity subpopulation 
comprising 60% of the cells, and a population of lower intensi­
ty comprising 40% of the cells (Fig.2A). This result suggested 
that the former population represented the majority of B-cells, 
and the latter, T-cells. Due to the very low expression of la-
number of cells 
7 0 0 • 
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spleen cells 
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T-cells 
J 
3 0 120 
1 1 • 
3 0 120 
relat ive fluorescence intensity 
Figure 2.Flowcytometric analysis of B10.D2 spleen cells (Panel A) and B10.D2 
T-cells (Panel Β), incubated with diluted (1:80) anti-BlO.D2 IgGl 
( ), or IgG2 ( ) alloantibodies. FITC-labelled anti-IgGl was 
used in a 1:100 dilution, and FITC-labelled anti-IgG2 consisted of 
1:1 mixture of anti-IgG2a (1:25) and anti-IgG2b (1:25). Each his­
togram represents the analysis of 30.000 cells. 
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Figure 3. Dose-dependent fluorescence of a high-intensity subpopulation 
(closed symbols) and a low-intensity subpopulation (open symbols) 
of B10.D2 spleen cells, incubated with anti-BlO.D2 IgGl (t;0) or 
IgG2 (Α;Δ) alloantibodies (Panel A), and of B10.D2 T-cells incu­
bated with IgGl (0—0) of IgG2 (Δ—Δ) alloantibodies (Panel B). 
Concentrations of FITC-labelled anti-IgG reagents were similar as 
in figure 2. 
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Figure 4. Passive enhancement by B6AF1 anti-BlO.D2 ascites and the IgGl and 
IgG2 fractions thereof, in B6JAF1 recipients of B10.D2 skin grafts. 
a) Injected on days 0, 2, and 4 after grafting, diluted in normal 
B6JAF1 serum 
b) Median Survival Time + Standard Deviation 
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antigens, T-cells might only be stained by anti-class I antibo­
dies and therefore, less brightly than B-cells, which can be 
stained by anti-class I, and by anti-class II antibodies (10,11). 
To test this possibility, purified T-cells were analyzed, and 
as is shown in Fig.2B, a single population was visualized, with 
similar fluorescence as the spleen cell subpopulation of low 
intensity. Further evidence for this interpretation was obtained 
by using anti-H-2 monoclonal anti-class I and anti-class II 
antibodies. BIO.A T-cells demonstrated a single discrete peak 
of low intensity following incubation with anti-class I,or with 
anti-class I + anti-class II antibodies. When BIO.A spleen cells 
were reacted with anti-class I antibodies, a discrete peak of 
similar intensity, though more diffuse, was visualized, but when 
anti-class I + anti-class II antibodies were used, a second, 
more brightly staining population was observed (data not shown). 
These results strongly suggest that the anti-class II activi­
ties of IgGl and IgG2 may be inferred by comparing the fluores­
cence intensity of the two subpopulations. By plotting the 
fluorescence channels with peak cell numbers, against the an­
tibody dilutions of IgGl and IgG2, staining of the two subpo­
pulations in the spleen cells and staining of the T-cells was 
similar over a broad dose range (Fig.3). This indicated that 
not only their anti-class I activities were similar, but also 
their anti-class II activities. The dose-dependent effects of 
IgGl and IgG2 were specific. Fluorescence of B6JAF1 control 
cells incubated with IgGl or IgG2 did not exceed channel 15, 
and the data in Fig.3 were corrected for these effects. 
Having demonstrated the similar in vitro activities of IgGl and 
IgG2, their activity to induce enhancement was investigated, and 
compared with the B6AF1 anti-B10.D2 ascites. As is shown in Fig. 
4, graded amounts of all three preparations induced dose-depen­
dent enhancement. Moreover, IgGl and IgG2 behaved essentially 
the same, and similar to the ascites fluid from which they ori­
ginated. Enhancement was specific. When the highest dose of 3 χ 
0.25 ml was analyzed in the BALB.K -* B6JAF1 control combination 
the normal survival of 12.6 days was not affected by either 
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IgGl, IgG2 or the ascites pool (data not shown). 
Because it has been proposed that opsonization of antigen-reac­
tive cells is involved in enhancement (5), opsonic activity was 
studied by the liver diversion of 51 Cr-labelled B10.D2 leuko­
cytes, coated with antibody in vitro, and injected i.v. into 
recipient mice. Using suspensions of viable cells without prior 
incubation with antibody, the percentage of cells moving to the 
spleen exceeded the number of cells sequestered in the liver, 
as was demonstrated previously (3). Cells incubated with IgG, 
however, are diverted away from the spleen, with a simultane­
ous increased localization in the liver. As is shown in Fig.5, 
opsonization by IgGl and IgG2 was specific, and almost identi­
cal. With the anti-B10.D2 ascites, similar opsonization was ob­
tained using concentrations which were 5 times lower. 
localization index 
2Θ -
24 -
20 -
16 -
12 -
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antibody (/jl) 
Figure 5. Localization indices in B6JAF1 recipients of B10.D2 leukocytes, 
incubated with anti-B10.D2 ascites (•-•), IgGl (·-·), and IgG2 
(Α-A) antibodies, and of control B6JAF1 leukocytes, incubated 
with the same preparations (open symbols). Each point represents 
the means + SD of at least 3 recipients, in 2 separate experiments. 
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DISCUSSION 
Our results demonstrate that there is a close correlation be­
tween the enhancing and opsonizing capacities of purified allo-
antibodies, and, that IgGl and IgG2 were equally effective. The 
effects of IgGl and IgG2 cannot be due to contaminations. First 
of all, enhancement and opsonization were specific. Neither the 
(NH4)2S04 precipitated ascites, nor the purified IgGl and IgG2 
fractions influenced the survival of control BALB.K skin graf­
ted onto B6JAF1 recipients, and only B10.D2 target cells were 
diverted to the liver, whereas control cells were not. Second­
ly, the contaminations of others (sub)classes in purified IgGl 
or IgG2 were too small to have significant effects. Contamina­
ting IgGl or IgG2 were at the highest amounts used, still far 
below the threshold concentrations that could induce enhance­
ment or opsonization. If the effects were caused by other im­
munoglobulin contaminants, one would expect enhancement and op­
sonization to correlate with their concentrations rather than 
with the amounts of IgGl and IgG2. This was clearly not the 
case, and therefore, we conclude that enhancement and opsoni­
zation were due to specific IgGl and IgG2 antibodies. 
In our former study on enhancement by IgGl and IgG2 we found 
that IgGl was 30-50 times less effective than IgG2 (2). However, 
this comparison was based on the amounts of protein injected 
and if the same is done for the results described here, IgGl 
appears to be nearly 2 times more efficient than IgG2. In the 
analysis of an additional anti-B10.D2 ascites pool, only IgG2 
antibodies could be purified, and no specific IgGl antibodies 
appeared to be present (data not shown). Thus, depending on the 
immunization procedure, and the interval between immunization 
and the collection of serum or ascites, different pools may con­
tain different amounts of specific IgGl and IgG2 antibody. This 
notion extends to the specificity of these antibodies. We have 
demonstrated previously that enhancement across H-2K plus I-
region МНС-differences can be mediated by anti-class I (12,13), 
and by anti-class II antibodies (4). However, the prolongation 
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of graft survival by anti-class I antibodies was much less than 
that by anti-class II antibodies. With the latter, enhancement 
was as efficient as with anti-class I + anti-class II sera (4). 
Thus, for the comparison of IgGl and IgG2, analysis of specific 
antibody activity is indispensable. 
Using two-stage cytotoxicity, specific and identical lysis of 
more than 95% of B10.D2 cells was demonstrated and this indica-
tes equal activities of anti-class I antibody in IgGl and IgG2. 
The same conclusion may be drawn from the immunofluorescence 
analysis of T-cells. The observation that in a spleen cell pre-
paration two subpopulations were visualized, one with similar 
intensity as isolated T-cells, and a second, more brightly stai-
ning population, comprising 60% of the cells, strongly suggests 
that the latter fraction consisted of B-cells. The more intense 
fluorescence of this fraction might be due to an increased ex-
pression of class I antigens, or to the staining by anti-class 
I + anti-class II antibodies. The first explanation is unlikely 
because with monoclonal anti-class I antibodies, no differences 
were observed between the staining intensities of purified T-
cells and spleen cells. Moreover, only after incubation of spleen 
cells with anti-class I + anti-class II monoclonal antibodies, 
two subpopulations were observed, similar to the histograms of 
B10.D2 spleen cells incubated with IgGl or IgG2 (data not shown). 
Therefore, binding of anti-class I + anti-class II antibodies 
is the most likely interpretation. The identical reactivities 
of IgGl and IgG2 indicate that both their anti-class I activi-
ties and their anti-class II activities were similar. 
As was reviewed recently by Voisin (14), controversial results 
have been obtained about the role of antibody (sub)classes in 
enhancement. However, decisions against the enhancing capacity 
of antibodies cannot be made if their specific activity is un-
known (15,16). The nature of the graft is also important, be-
cause with tumors, cytotoxic effects by IgG2 alloantibodies have 
been shown to interfere with enhancement (17-19). Our results 
demonstrate that meaningful comparisons of the effects of IgGl 
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and IgG2 can only be made with in vitro characterized prepara-
tions. In this way we could show that IgGl and IgG2 were equal-
ly effective. 
The observed opsonizing capacities of IgGl and IgG2 are in agree-
ment with recent reports from others. Heusser et al (20) have de-
monstrated that macrophages and macrophage-like cell lines bind 
aggregated myeloma proteins of IgGl,IgG2a andIgG2b subclass e-
gually well. Similarly, it has been reported that phagocytosis 
by peritoneal exsudate cells and mouse spleen cells , was nearly as 
effective with IgGl as with IgG2,using hybridoma antibodies to 
sheep red blood cells (21). Also in the human, mouse IgGl mono-
clonal anti-T cell antibody was shown to be highly opsonic (22). 
The close correlation between the enhancing and the opsonizing 
capacity of IgGl and IgG2 supports the concept that opsoniza-
tion of antigen-reactive cells by immune complexes may be in-
volved in the induction of enhancement (5). We have demonstra-
ted previously that the comparison of IgG and IgM leads to a 
similar conclusion, because strongly opsonizing IgG antibodies 
were enhancing, whereas non-opsonizing IgM antibodies were not 
(3). However, this correlation may not be absolute, and a cer-
tain degree of opsonization does not necessarily predict the 
level of enhancement. Recently, we have compared the enhancing 
and opsonizing capacities of monoclonal alloantibodies, and de-
monstrated that monoclonal antibodies were as effective as a 
conventional alloantiserum in opsonization, but dit not enhance 
skin graft survival (in preparation). Therefore, opsonic acti-
vity may be a prerequisite for enhancing antibodies, but it can-
not guarantee that enhancement will invariably occur. 
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CHAPTER 6 
IMMUNE REGULATION BY MONOCLONAL ANTIBODIES: FAILURE TO ENHANCE 
MOUSE SKIN ALLOGRAFTS 
Simon P.M. Lems, Wil J.M. Tax, Peter J.A. Capel 
and Robert A.P. Koene 
From the Department of Medicine, Division of Nephrology 
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SUMMARY 
Monoclonal anti H-2 alloantibodies were analyzed for their ca-
pacity to enhance the survival of BIO.A skin, grafted onto 
B10.D2 recipients. Included were 5 anti-class I and 4 anti-class 
II antibodies. In contrast to conventional B10.D2 anti-BlO.A 
serum, none of the individual anti-class I or anti-class II mo-
noclonal antibodies induced enhancement. The same negative re-
sults were obtained with various mixtures of anti-class I, anti-
class II, or anti-class I + anti-class II antibodies. The fai-
lure to induce enhancement was not due to inefficient antigen 
binding in vivo, because monoclonal antibodies were as effec-
tive as conventional B10.D2 anti-BlO.A serum in the induction 
of acute antibody-mediated graft rejection, and in the opsoni-
zation of 51Cr-labelled BIO.A leukocytes, injected into B10.D2 
recipients pretreated with antibody. These results demonstrate 
that monoclonal antibodies cannot always substitute for conven-
tional sera, at least not in immune regulation. They also show 
that, although opsonization may be a prerequisite for the in-
duction of enhancement, it does not guarantee that enhancement 
will invariably occur. 
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INTRODUCTION 
The administration of antibodies directed against the MHC-anti-
gens of an allograft may have destructive, as well as protec-
tive effects (1). These opposite effects, acute antibody-medi-
ated graft rejection (AAR) on the one hand, and prolongation of 
graft survival (Immunological Enhancement)on the other,have been 
studied extensively, in order to gain insight into the mecha-
nisms underlying these phenomena, and to define enhancing anti-
body preparations without destructive activity. To that end, 
complex allosera have been fractionated in various immunoglo-
bulin (sub)classes, and also according to their anti-class I 
and anti-class II specificity. However, from recent reviews it 
is evident that the results obtained in different laboratories 
are controversial (2,3). This may, at least in part, be due to 
the high demands for purity which have to be met. The use of 
monoclonal antibodies would obviate these limitations, because 
the required specificity and antibody (sub)class can be selec-
ted for. 
In addition, an analysis of allograft enhancement with monoclo-
nal antibodies might lead to a better understanding of the me-
chanism of this phenomenon. Previous studies from our labora-
tory (4,5) and from others (6) have demonstrated that enhance-
ment of allografts is Fc-dependent. Furthermore, since enhance-
ment is specific, it is evident that binding to alloantigens 
by alloantibody is required. Therefore, complex formation of 
antigen and alloantibody, and the subsequent interaction of the 
Fc-part of complex-bound alloantibody with secondary effector 
systems, appears to be fundamental in the mechanism of enhan-
cement. Several models are compatible with this view. 
It has been suggested that antibody might reduce the antigenic 
stimulus, by the opsonization of donor passenger leukocytes (7). 
Alternatively, enhancement may involve an effect on antigen-
reactive cells (ARC) of the host. Antigen-specific lymphocytes 
may bind immune complexes consisting of released graft antigen 
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and alloantibody. Upon binding, the cell may be inactivated, 
either by the interaction of the Fc-part of the antibody with 
Fc-receptors on this lymphocyte (2), or antigen-reactive cells 
may be opsonized by complexes, resulting in their phagocytosis 
(8). This latter phenomenon has been called antigen-reactive 
cell opsonization (ARCO). 
Two predictions can be made from these models. Firstly, enhan-
cing antibody should be cytophilic and, in case of ARCO or pas-
senger cell opsonization, opsonic. Secondly, enhancement should 
be a non-determinant specific phenomenon: antibody directed a-
gainst one or a few determinants on the antigen, should suppress 
the response to the rest of the determinants on that antigen. 
In case of passenger cell opsonization, binding to any antige-
nic determinant will opsonize the whole cell, and will reduce 
the antigenic stimulus also for those lymphocytes, recognizing 
determinants different from the one antibody was directed to. 
Similarly, host lymphocytes can only interact specifically with 
complexes which display free antigenic determinants and, there-
fore, antibodies binding to only a few of all determinants of 
the antigen, will allow the interaction of complexes also with 
those host lymphcoytes which are directed against different epi-
topes. Therefore, manipulation of the number of antibody speci-
ficities, which can be done using various monoclonal antibodies, 
may provide further insight into the mechanism of enhancement. 
Based on these considerations, we have analyzed the capacity of 
monoclonal alloantibodies to enhance mouse skin allografts, in 
relation with their opsonizing capacity. Because the enhancing 
capacity of conventional IgG2 antibodies is not disputed, mono-
clonal antibodies of this subclass were selected. It will be 
demonstrated that monoclonal antibodies were as effective as a 
conventional alloantiserum in the induction of acute antibody-
mediated rejection (AAR) and in opsonization, but that indivi-
dual anti-class I, anti-class II, as well as various mixtures 
thereof, did not induce enhancement. 
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MATERIALS AND METHODS 
Animale. Inbred strains of BlO.D2/Sn-new (H-2 ), BIO.A (H-2a) and BALB/c 
(H-2 ) were originally obtained from Jackson Laboratory (Bar Harbor, Maine) 
and C57BL/6Rij mice from the Radiobiological Institute, Rijswijk, The Nether-
lands. BALB/cBykh (H-2 ) and BALB/cH-2 mice were kindly supplied by Dr. 
P. Démant. BALB.K (H-2 ) mice were obtained from Olac Ltd. Blackthorn, U.K. 
MonoaZonaZ antibodies. A total of 9 monoclonal alloantibodies, comprising 5 
anti-class I and 4 anti-class II antibodies, was selected for this study. 
For convenience, they are numbered from 1 to 9 and characteristics are lis-
ted in Table I. 
Table I. Monoalonal IgG2 alloantibodies analyzed for their enhanoing capa-
city 
No. Code 
anti-class I (H-2k) 
1. 3-1-3-1 
2. 11-4.1 
3. H100-27.R55 
4. H100-30.R26 
5. HI00-5.R4 
anti-class II(H-2 ) 
6. 2-2-1 
7. H116-32 
8. 11-5.2 
9. 11-3.25 
Specificity 
recognized 
H-2.5 
H-2Kk 
H-2.25 
H-2.5 
H-2.11 
lak 
la.19 
la.2 
la.17 
Y2-subclass 
b 
a 
a 
b 
a 
a 
b 
b 
b 
Cytotoxic 
titer 
5 
5 
25 
5 
5 
2 
χ 10 5 
4 
χ 10 
χ 10 
iob 
4 
χ 10 
χ 10 5 
10 4 
10 4 
χ 10 
a) Cytotoxic titer was determined using spleen cells of the skin graft do­
nor strain BIO.A 
Numbers 1 and 6 were produced in our laboratory, by immunization of BALB/c 
mice with BALB.K spleen cells and fusion with Sp2/0 Agl4 according to stan­
dard procedured described elsewhere (9). Cells of hybrid 11-4.1, producing 
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no. 2, were kindly provided by the Salk Institute, San Diego, CA. Antibo­
dies 1, 2, and 6 were produced in ascites fluid using BALB/c mice. Antibo­
dies 3, 4, 5 and 7 were generous gifts of Dr. K. Rajewsky. In addition to 
the characteristics listed in Table 1, detailed information about these pre­
parations can be found in reference 10. Antibodies θ and 9 were purchased 
from Becton Dickinson, Mountain View, CA. Further characteristics of these 
products, and of antibody no. 2 can be found in reference 11. All prepara­
tions were diluted in 10% normal B10.D2 serum and sterilized by passage 
through a 0.2 μ pore size membrane filter (Schleicher and Schüll, Dassel, 
West Germany). 
Conventionai anti-sera. Alloantisera were prepared by weekly intraperitoneal 
injections of a suspension of 5 χ 10 lymphoid cells in complete Freund's 
adjuvant (CFA). This procedure resulted in ascites production within 5-6 
weeks. Ascites pools of B10.D2 anti-BlO.A, and BALB/c anti-BALB.K were trea­
ted with (ΝΗ4)2304 at 50% saturation and the precipitated proteins, solubi-
lized and dialyzed against PBS, were sterilized by passage through a series 
of membranes filters (Schleicher and Schuil, Dassel, West Germany) with de­
creasing pore sizes ranging from θ μ to 0.2 μ. Anti-lymphocyte serum (ALS) 
Q 
was raised in goats by a subcutaneous injection of 5 χ 10 C57BL/6RÌJ lym-
p 
phocytes suspended in CFA followed by 2 weekly i.v. injections of 5 χ 10 
lymphocytes in saline. Anti-mouse erythrocyte antibodies were removed from 
the ALS by adsorption with C57BL/6Rij erythrocytes. Antisera used in vivo 
were heat-inactivated at 56 С for 30 min. 
Cytotoxic assay. The in vitro cytotoxic activity of monoclonal, and of con­
ventional antibodies was determined by trypan blue exclusion with BIO.A 
spleen cells, freed of erythrocytes by treatment with NH4C1. Using microti-
ter plates (Greiner, Nürtingen, West Germany), 25 μΐ of a cell suspension 
(5 χ 10 /ml) were incubated with 25 μΐ of a dilution series of alloantibody 
in Hanks' balanced salt solution supplemented with 0.1% BSA, and 25 μΐ dilu­
ted (1:4) rabbit serum as the complement (C) source,for 30 min at 37 С The 
rabbit sera were preselected, and only those sera that lysed 10% or less of 
the mouse lymphocytes in the absence of alloantibody were used. 
Liver diversion assay. The opsonizing capacity of antibodies was analyzed 
in two ways. BIO.A leukocytes, labelled with 51Cr and incubated with mono-
8Θ 
clonal, or conventional alloantibody in vitro, were injected i.v. into re­
cipient B10.D2 mice as described earlier (12). In addition, a system was 
employed in which opsonization as well as the interaction of alloantibody 
and target cells in vivo was analyzed. For this purpose, B10.D2 mice were 
injected i.p. with alloantibody, 24 hr before the i.v. injection of 51Cr-
labelled BIO.A leukocytes. Target cells were allowed to react with alloan­
tibody in vivo, and opsonization was analyzed after 3 hr, by the removal of 
livers and spleens for gamma counting. In control experiments, labelled 
B10.D2 spleen cells were used. These cells were either incubated with anti-
B10.A antibody in vitvo, or injected directly into recipients pretreated 
with antibody. Doses of antibody are expressed as cytotoxic units (CTU). One 
CTU is defined as the amount of alloantibody lysing 50% of 1.25 χ 10 BIO.A 
leukocytes in the cytotoxicity assay. Results of the opsonization experi­
ments are expressed as localization indices (L.I.). These were calculated 
by dividing the mean liver/spleen ratio of antibody-treated cells by the 
mean liver/spleen ratio of untreated cells. 
Enhancement of allografts. B10.D2 recipients grafted with BIO.A tail skin, 
as described earlier (13), were injected i.p. with 0.25 ml diluted monoclo­
nal antibody, mixtures thereof, or with conventional allosera, on days 0, 2, 
and 4 after grafting. The amounts injected were based on the in vitro cyto­
toxic activity with BIO.A spleen cells, and they are expressed as cytotoxic 
units. 
Acute antibody-mediated rejecticm. Acute rejection of well-established grafts 
on immunosuppressed recipients was induced by i.v. injection of alloantibo­
dy together with 0.25 ml rabbit С at day 7 after grafting (14). The reci­
pients were immunosuppressed by i.p. injections of 0.25 ml ALS on days 0, 2, 
and 4 after grafting. The rabbit serum used as С source was preselected and 
had no cytotoxic effect on mouse lymphocytes in vitro. 
RESULTS 
Enhancement by conventional alloserum. Since the monoclonal an-
tibodies selected for this study were directed against the H-2 
haplotype, and were produced by BALB/c (H-2 ) mice, a transplan­
tation model was chosen consisting of B10.D2 (H-2 ) recipients 
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which were grafted with BIO.A (H-2 ) donors. In this way, the 
H-2 barrier consisted of the H-2K and the I-region (15). 
Untreated recipients rejected donor skin grafts with a median 
survival time of 10.5 + 1.1 days, and the injection of 10% 
B10.D2 serum which was used as a diluent for all preparations 
had no significant effect on graft survival (Fig.l). 
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Figure 1. Passive enhancement by B10.D2 anti-BlO.A antiserum in B10.D2 re­
cipients of BIO.A skin grafts. 
a) Median Survival Time + Standard Deviation, (applies also to 
Figs.2-4) 
Enhancement of BIO.A skin, grafted onto B10.D2 recipients has 
been reported by Staines et al (16) , and this is confirmed here. 
Conventional B10.D2 anti-BlO.A serum induced a dose-dependent 
prolongation of skin graft survival, in comparison with controls 
(Fig.l). This enhancing effect was specific, because the sur­
vival of BALB/c skin grafted onto the H-2L loss-mutant BALB/c 
H-2 was not affected by this antiserum (data not shown). 
Effects of monoclonal antibodies on graft survival. The effects 
of anti-class I monoclonal antibodies on skin graft survival 
are shown in Fig.2. In only one instance, administration of 1500 
χ 10 CTU of monoclonal no.l, a result suggestive of enhance­
ment was obtained, but a twofold increase in the dose, reduced 
graft survival to control levels again, as was the case for all 
other monoclonal anti-class I alloantibodies. 
We have previously reported that enhancement by anti-H-2K anti­
bodies across a class I + class II H-2 barrier can be demon­
strated, although prolongation of graft survival is small (17, 
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Figure 2. Effects of anti-class I (H-2 ) monoclonal alloantibodies on the 
survival of BIO.A skin, grafted onto B10.D2 recipients 
1 8 ) . On t h e o t h e r hand, enhancement by a n t i - l a a n t i b o d i e s a c r o s s 
a H-2K + I - r e g i o n b a r r i e r i s m o r e r e a d i l y o b t a i n e d , aswas r e p o r ­
t e d b y J a n s e n e t a l (19) . When we t e s t e d t h e m o n o c l o n a l a n t i - c l a s s 
I I a l l o a n t i b o d i e s , g r a f t s u r v i v a l was somewhat p r o l o n g e d , b u t 
none of t h e a n t i b o d i e s a n a l y z e d was a b l e t o i n d u c e enhancement of a 
magni tude comparable t o t h a t of c o n v e n t i o n a l BIO.02ant i -B10.A 
serum ( F i g . 3 ) . 
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Figure 3. Effects of anti-class II (H-2 ) monoclonal alloantibodies on the 
survival of BIO.A skin, grafted onto B10.D2 recipients 
The same h e l d t r u e when v a r i o u s m i x t u r e s of a n t i - c l a s s I , a n t i -
c l a s s I I , and a n t i - c l a s s I + a n t i - c l a s s I I a n t i b o d i e s were ana­
l y z e d ( F i g . 4 ) . 
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Figure 4. Effects of mixtures of monoclonal alloantibodies on the survival 
of BIO.A skin, grafted onto B10.D2 recipients. 
a) Combinations consisting of equal amounts of individual compo­
nents 
Induation of acute vejeetion (AAR). Although the interaction of 
monoclonal antibodies with BIO.A alloantigens was demonstrated 
in vitro, it is not self-evident that a similar interaction oc­
curs in vivo. In order to exclude that inefficient antigen bin­
ding in vivo was responsible for the lack of enhancing capaci­
ty, the interaction of monoclonal antibodies with the graft an­
tigens in vivo was tested by their ability to induce AAR. Gra­
ded amounts of monoclonal no.2, and of the mixture (1-5 + 6-8), 
together with 0.25 ml rabbit С were administered i.V. to immu-
nosuppressed B10.D2 recipients of BIO.A skin, on day 7 after 
grafting. The results given in Table II show that preparations 
of monoclonal antibodies, that had a cytotoxic activity in vi­
tro similar to that of the B10.D2 anti-BlO.A serum, were equal­
ly effective in the induction of complete necrosis of the grafts 
within 48-72 hr. Because anti-class II antibodies are not capa­
ble of the induction of AAR (19), use was also made of 1251-
labelled antibodies to demonstrate interaction with the graft 
antigens in vivo. The results of these studies clearly demon­
strated the specific binding of both anti-class I, and anti-
class II antibodies to the graft antigens (De Waal et al, in 
preparation). 
92 
Table i l . Induction of acute antibody-mediated rejection (AAR) by B10.D2 
anti-BlO.A antisemm and by monoclonal alloantibodies 
cru 
a) b) 
Treatment administered AAR 
(xlO-3) 
B10.D2 anti-BlO.A serum 0.16 2/5 
0.8 8/9 
4 5/5 
Monoclonal antibody no.2 0.32 2/3 
3.2 3/3 
32 4/4 
Monoclonal mixture 0.16 1/5 
(1+2+3+4+5) + (6+7+8) 0.8 7/9 
4 5/5 
a) AAR is evoked by administration of alloantibody together with 0.25 ml 
rabbit С to immunosuppressed B10.D2 recipients of BIO.A skin, on day 7 
after grafting 
b) Number of recipients showing complete necrosis of the graft within 48 to 
72 hr devided by the total number injected 
Opsonization by monoclonal antibodies. Because according to the 
ARCO hypothesis, opsonization op antigen-reactive cells is in­
volved in the induction of enhancement (8), we analyzed whether 
the failure of monoclonal antibodies to induce enhancement 
could be correlated with their opsonizing capacity. For this 
purpose, the monoclonal mixture (1-5 + 6-8) was compared with 
the conventional B10.D2 anti-BlO.A serum. Opsonization was ana­
lyzed by the in vivo liver diversion of 51Cr-labelled BIO.A 
leukocytes, coated with graded amounts of monoclonal, or conven­
tional alloantibody in vitro. Liver diversion was also studied 
using uncoated 51Cr-labelled BIO.A leukocytes, which were al­
lowed to react with alloantibody injected into the recipient 
24 hr before the injection of cells. Since the results with both 
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assays were identical, only those of the latter are shown. Over 
a broad dose range, monoclonal antibodies were as effective as 
B10.D2 anti-BlO.A serum in the opsonization of BIO.A target 
cells (Fig.5). Opsonization of uncoated cells in recipients 
pretreated with antibody therefore, provided in addition to the 
induction of AAR, a second proof of the interaction of monoclo­
nal antibodies with BIO.A antigens -in vivo. The effects of mo­
noclonal, and conventional B10.D2 anti-BlO.A antibodies were 
specific, because the distribution of B10.D2 control cells was 
unaffected in both assays (Fig.5). 
localization index 
16 
14 
12 
10 
6 -
о 160 eoo 4000 
antibody administered (CTU) 
Figure 5. Opsonization of BIO.A leukocytes (closed symbols), and of control 
B10.D2 leukocytes (open symbols), in B10.D2 recipients, injected 
with conventional B10.D2 anti-BlO.A serum (Α-A) or with a mixture 
of monoclonal antibodies ( · - · ) . Each point represents the means 
+ S.D. of 4 recipients, in 2 separate experiments 
DISCUSSION 
The r e s u l t s of t h i s s t u d y d e m o n s t r a t e t h a t a l t h o u g h monoclonal 
a n t i b o d i e s were a s e f f e c t i v e as a c o n v e n t i o n a l a l l o s e r u m i n op-
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sonization and in the induction of AAR, they failed to induce 
enhancement. In order to explain this failure, their proper­
ties have to be considered. The antibodies analyzed are ofBALB/c 
Igh allotype and IgG2 subclass. Furthermore, they have, except 
no.8, a public specificity, and their avidity for BIO.A alloan-
tigens is unknown. 
It is highly unlikely that the differences in allotypes between 
the monoclonal antibodies and the conventional alloantiserum, 
which is of the Igh allotype, explains the failure of monoclo­
nal antibodies to induce enhancement, because it has been de­
monstrated in the rat that even xenogeneic sera are able to en­
hance kidney allografts (20,21). Moreover, this possibility is 
ruled out by our own observation that a BALB/c anti-BALB.K se­
rum was as effective as the B10.D2 anti-BlO.A serum in the in­
duction of enhanced BIO.A skin graft survival in B10.D2 reci­
pients (data not shown). 
It is also unlikely that the IgG2 subclass used might explain 
our results, because enhancement by alloantibodies of this sub­
class was demonstrated twice in our laboratory in a mouse skin 
graft model (22,23), and also by others, in the enhancement of 
mouse tumors (24-30) and rat kidneys (31). 
It was also established in our previous studies that enhance­
ment across H-2K + I-region differences cannot only be induced 
by anti-class II antibodies (19), but also by anti-class I an­
tibodies (17,18), although the effects with anti-class I prepa­
rations were relatively weak. These observations were made in 
models different from the one used in this study, but enhance­
ment with anti-class II antibodies has also been reported using 
the ΒΙΟ .Α-ί-ΒΙΟ .D2 combination (16). Thus, the results of various 
studies support the observation that both anti-class I and anti-
class II antibodies are enhancing (2,3). Because not only the 
anti-class I, but also the anti-class II and the mixed anti-
class I + anti-class II monoclonal antibodies failed to induce 
enhancement, it is unlikely that the H-2 barrier of the model 
95 
has been a responsible factor. 
To exclude that the negative results were due to inefficient 
antigen binding, the activity of monoclonal antibodies was tes­
ted in vitro and -in vivo. Antigen binding and activation of 
rabbit С in vitro was demonstrated by lymphocytotoxicity. Inter­
action with the BIO.A antigens in vivo was shown by the obser­
vation that in terms of cytotoxic units, monoclonal antibodies 
were as effective as a conventional alloantiserum in the induc­
tion of AAR and in opsonization. Moreover, by using 1251-label-
led preparations, specific binding of both anti-class I and an­
ti-class II monoclonal antibodies to the graft antigens could 
be demonstrated (data not shown). 
Therefore, the interpretation of our results is first and fore­
most dependent on unanswered questions concerning the mecha­
nism of immunological enhancement. Two well established pheno­
mena are relevant to the results discussed here. Firstly, the 
observations that enhancement is Fc-dependent (4-6) and second­
ly, the notion that antibody directed against one or a few de­
terminants on the antigen, suppresses the response to the rest 
of the determinants on that antigen (16,32-35). A striking 
example of the latter phenomenon, having special relevance to 
our data, is the recent demonstration of rat kidney enhancement 
by monoclonal antibodies (21,36,37). 
It was suggested recently that, in kidney allograft enhancement 
in the rat, antibody may act by the opsonization of passenger 
leukocytes, notably the interstitial dendritic cells, thereby 
reducing the immunogenic stimulus (7). This explanation is com­
patible with the two phenomena described above. It will undoub­
tedly also occur in mouse skin allografts since our data showed 
that 51Cr-labelled BIO.A leukocytes were opsonized. Neverthe­
less, our strongly opsonizing monoclonal antibodies failed to 
induce enhancement and, therefore, opsonization of passenger 
leukocytes cannot be a major mechanism in the enhancement of 
mouse skin, grafted across class I + class II MHC-differences. 
96 
This view is in agreement with recent results of Woodward et al 
(38), who demonstrated that in the case of class I + class II 
H-2 differences, removal of passenger cells, by using radia-
tion chimeras, did not influence skin graft survival. However, 
it does not exclude that this mechanism is operative in kidney 
graft enhancement, and in view of the greater difficulty of en-
hancing skin relative to a kidney allograft (39), this might 
explain why kidney allografts were shown to be enhanced by mo-
noclonal antibodies in contrast to mouse skin. 
Other hypotheses on the mechanism of enhancement focus on the 
antigen-reactive cells of the host, which, upon binding to an-
tigen-antibody complexes, may directly be inactivated (2), or 
may be removed by phagocytosis (8). Our previous data (12,23) 
showed a strong correlation between the opsonizing and the en-
hancing capacity of alloantibodies, and therefore, we favour 
the idea that antigen-reactive cells are opsonized by immune 
complexes, and are removed by phagocytosis. However,the results 
reported here indicate that the argument that enhancing anti-
bodies are opsonizing, cannot be turned around. Opsonization 
may be a prerequisite, but it is no guarantee for enhancement, 
and other factors, like the nature of the antigen-antibody com-
plexes and the host cells they interact with, will be important 
as well. 
It is not known which antigen-reactive cells, e.g. regulator 
cells or effector cells, must be eliminated to induce enhance-
ment. If the ARCO hypothesis is right, we must conclude that 
the complexes of antigen and monoclonal antibodies, presumably 
formed in our experiments, did not react with the right type 
of host cells. Some clues may come from recent findings on the 
composition of conventional anti-la antisera. It has been amply 
documented that la-antibodies are most important in the enhan-
cement of organs and tissues grafted across class I + class II 
differences. These conventional la-antisera have now been shown 
to contain antibodies against unique I-region encoded T-cell 
products, different from conventional la-antigens present on 
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B-cells (40). Furthermore, evidence has been accumulating for 
the presence of new, previously unknown class I molecules as 
well (41). Our panel of monoclonal antibodies did not react 
with non B-cell la-antigens, and it is very well possible that 
specificities for new class I molecules were lacking as well. 
Thus, their limited reactivity may explain the failure to in-
duce enhancement. 
In conclusion, we have shown that monoclonal antibodies were as 
effective as a conventional alloantiserum in opsonization and 
in the induction of AAR, but that they failed to induce enhan-
cement. These results indicate that enhancement is not only de-
pendent on the opsonizing capacity of anti-class I and anti-la 
alloantibodies, but also on their specificity for thusfar un-
known H-2 products. 
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Rejection of Long-Surviving Mouse Skin Allografts 
After Withdrawal of Cyclosporin A Therapy 
S. P M. Lems. Ρ J A Capel, and R A P . Koene 
THE immunosuppressive effects of cyclo­sporin A (CY-A) as demonstrated in 
various animal systems'2 and in man3 were 
recently reviewed by Calne.4 Most promising 
thusfar are the results of Green and Allison5 
and of Dunn et al.6 using rabbit kidney 
allografts. Recently, Green et al. again 
demonstrated that extensive prolongation of 
rabbit kidney allograft survival occurs after a 
short-term treatment with CY-A.7 Moreover, 
the unresponsiveness appeared to be donor-
specific and once induced, universal, skin 
grafts being accepted as well. In mice, treat­
ment with CY-A prolonged skin allograft 
survival in a model with multiple non-H-2 
differences.' In a previous report,8 we have 
described the influence of CY-A on the 
survival of mouse skin grafted across a major 
histocompatibility barrier The immunosup­
pressive effects of CY-A were demonstrated, 
but the prolongation of graft survival was 
clearly dependent on the continuous adminis­
tration of CY-A. Since this finding differed 
from the results obtained in the rabbit, we 
have extended our observations by studying 
the dose-effect relationships in our model. 
Furthermore, studies in thymectomized recip­
ients demonstrate that the rejection that 
invariably occurs after withdrawal of the drug 
is most likely caused by the recovery of 
lymphocytes on termination of treatment and 
not to the appearance of newly matured Τ 
cells. 
MATERIALS AND METHODS 
Inbred lines of BIO D2/new Sn and of A/HeJ mice 
were originally obtained from the Jackson Laboratory, 
Bar Harbor, Me C57BL6/Rij mice were obtained from 
the Radiobiological Institute TNO, Rijswijk, The 
Netherlands (C57BL6/Rij χ A/HeJ)F l, B6AF, hybrids 
were raised in the laboratory 
Tail skin of male BIO D2 donors was grafted onto the 
flank of male B6AF, recipients (H-2d — H-2"'b) by a 
modification of the "fitted graft" technique Instead of 
plaster bandage, a Band-aid was used to cover the graft 
Transplantation Proceedings, Vol XII. No 2 (June), 1980 
for 8 days The fate of the grafts was followed by daily 
macroscopic inspection Grafts were considered to be 
rejected when no viable epidermis remained The median 
survival lime (MST) and the standard deviations were 
calculated according to Litchfield,9 with an anthmatical 
adaptation Thymectomy was performed in 4-week-old 
mice according to Herbert l 0 Sham-thymectomized 
animals were prepared by the same procedure except that 
no thymic glands were removed The animals were used 
as skin grafi recipients 3 weeks after the operation On 
termination of treatment, successful removal of the 
thymus was assessed by macroscopic inspection CY-A 
was dissolved in olive oil at concentrations of 10 and 20 
mg/ml by stirring in a 620C waterbath for 2 hr Once 
dissolved, the solution could be kept for several weeks at 
room temperature CY-A doses were based on the mean 
body weight of the recipients al the onset of the treatment 
period Usually, the initial body weight averaged 26 5 ± 2 
g, increasing lo 28-30 g 6 weeks later Oral CY-A 
treatment was taken very well by all animals, except for a 
slight weight loss in the first days of treatment 
RESULTS 
Oral treatment of recipient mice appeared 
to be most convenient. Daily administration 
of olive oil as is expressed in group 2 (Table 1) 
resulted in graft survival times similar to 
those observed for the untreated controls in 
group 1. Administration of CY-A was started 
with a daily dose of 25 mg/kg body weight for 
13 days. This protocol resulted in a slight but 
significant increase in graft survival (group 
3). However, using a more extended adminis­
tration period, all grafts were rejected during 
treatment (group 4), suggesting that a subop-
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gen, Nijmegen, The Netherlands 
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Table 1. Graft Survival With 25 mg/kg Cycloaporln A 
Group 
1 
2 
3 
4 
Treatment 
None 
Olive oil 
daily Irom - 2 
CY-A daily Irom 0 - 13 
CY-A daily Irom O-rejeclion 
Graft Survival 
(Day.) 
10 10 10 10 10 
11 11 12 12 12 
9 10 11 11 
11 12 13 13 14 
13 13 14 16 16 
14 15 i e 18 I B 
MST ι SD' 
(Day·) 
1 0 3 ± 1.1 
10 8 ± 1.1 (NS) 
1 3 5 ± 1 I t 
1 5 2 ± 1 I t 
NS, nol significantly dilferenl from untreated controls 
'Median survival time ± standard deviation 
t p < 0 001 (Student's t test) in comparison with untreated controls 
timal dose was given. Therefore, CY-A doses 
were raised to 75 mg/kg body weight. Signif­
icant prolongation of graft survival was 
demonstrated in the animals receiving CY-A 
on days - 1 , 1 , and 3 (Table 2, group 5), and 
administration of CY-A every other day for 
17 days resulted in a prolonged survival time 
of 23.1 days (group 6). With the latter proto­
col, however, one graft was lost during treat­
ment at day 15, and this again suggested 
suboptimal conditions. Therefore, daily treat­
ment with 75 mg/kg body weight was 
adopted, starting 2 days before transplanta­
tion. Using this protocol, none of the grafts 
was rejected during administration, not even 
during a period of 50 days (group 9). 
Nevertheless, withdrawal of CY-A resulted in 
rejection in all experimental groups (groups 7, 
8, and 9). Strikingly, the time interval 
between withdrawal of treatment and rejec­
tion in these animals closely equalled the 
survival times observed in untreated con­
trols. 
To exclude that newly matured Τ cells were 
responsible for the observed rejection, graft 
survival was studied in thymectomized and in 
sham-thymectomized recipients. CY-A was 
administered at 75 mg/kg body weight for 
various periods, starting at the day of trans­
plantation. Graft survival times in thymec­
tomized recipients could not be distinguished 
from graft survival in the sham-thymectom­
ized animals (Table 3), both being similar to 
the untreated controls receiving only CY-A 
(Table 2). In each group, some animals 
received CY-A starting at 2 days before 
transplantation, but since the results were 
similar, the survival times with these slightly 
differing treatment protocols have been put 
together in the table. 
DISCUSSION 
The immunosuppressive effects of CY-A in 
a mouse skin graft model are evident from the 
data reported here. However, substantial 
prolongation of graft survival was clearly 
Table 2. Graft Survival With 75 mg/kg Cyclosporin A 
Group 
5 
6 
7 
β 
9 
CY A Treatment 
(75 mg/kg) 
Day - 1 , 1. 3 
Every other day 
from - 1 to 18 
Daily from - 2 to θ 
Daily Irom 2 10 2 8 
Daily Irom - 2 to 5 1 
13 
14 
2 4 
17 
8 2 
Grail Sirvival 
(Day·) 
13 13 13 
15 15 17 
15 22 2 3 
2 7 2 8 3 1 
17 17 17 
18 18 2 0 
3 6 3 8 3 6 
6 3 6 4 64 
14 
19 
2 3 
3 6 
17 
2 0 
3 6 
6 7 
MST ± SD· 
(Daya) 
1 3 6 ± 1 1 
2 3 1 ± 1.2 
1 7 0 ± 1 1 
35.5 ± 1 0 
6 3 2 ± 1 0 
Median Interval Between 
Withdrawal ol Treatment 
and Rejection ± SD 
(Day·) 
1 0 2 ± 1.1 
1 0 5 ± 1 0 
13 1 ± 1 1 
* Med ι an survival time ± standard deviation 
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Tabi· 3. Graft Survival In Thymactomlzed a 
With 75 mg /I 
CY A Trealmenl Grafi Survival 
S/T* (Daily. 75 mo/Kg) (Days) 
None 
Day 0-13 
Day 0-26 
Day 0-51 
Day 0-101 
None 
Day 0-13 
Day 0-26 
Day 0-51 
Day 0-101 
10 11 12 12 
12 13 13 IS 
19 19 20 22 22 
35 36 37 37 36 
62 63 63 
112 114 122 
10 11 11 11 
11 12 12 12 
16 19 20 
21 21 23 
34 35 35 37 
38 3B 38 39 
62 62 62 62 
64 64 64 66 
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'S. sham-lhymedomized, T, thymeclomized 
tMedian survival lime ± standard deviation 
dependent on the continuous administration 
of a sufficient amount of CY-A. Doses of 25 
mg/kg administered orally5" or intramuscu­
larly6 prevented kidney allograft rejection in 
rabbits and substantially prolonged heart 
graft survival in pigs. Similar doses injected 
subcutaneously allowed the establishment of 
functional histoincompatible marrow grafts in 
the rat.12 Our data show, however, that in a 
mouse skin graft model, graft rejection was 
delayed but not prevented during treatment 
with this dose of CY-A. Most likely, this 
phenomenon again reflects the already well 
documented differences in the intensity of 
rejection of various organs and tissues, skin 
being highly immunogenic in this respect.'3 
Nevertheless, if CY-A was administered daily 
at the higher dose of 75 mg/kg, graft rejec­
tion during treatment could be prevented. 
However, termination of treatment resulted 
invariably in prompt graft rejection even in 
thymeclomized animals. On the basis of the 
in vitro toxicity of CY-A for lymphoblasts,'4 it 
was suggested that CY-A acts in vivo by the 
suppression of clones of lymphocytes respond­
ing to a specific antigenic challenge.5 The 
state of specific unresponsiveness observed in 
rabbits after termination of CY-A treatment 
I In Sliam>Thymeclomlzed Recipient· Treated 
Cyclosporin A 
Median Interval Between 
Withdrawal ol Treatment 
12 
15 
24 
39 
11 
15 
21 
25 
36 
40 
64 
67 
MST ± sot 
(Deya) 
11 7 ± 1 1 
199 ± 1 1 
36 4 - 10 
62 2 ± 1 0 
113 1 2 10 
110 ι 1 1 
20 2 ± 1 1 
364 ± 1 0 
62 7 ± 1.0 
might suggest that CY-A not only suppresses, 
but also eliminates, the responding clones.7 
However, the skin graft rejection we observed 
in thymeclomized and long-term CY-A-
treated mice shows that the effect of CY-A is 
reversible. These differences in responsiveness 
after termination of CY-A treatment might 
be explained by the hypothesis that analogous 
to the different susceptibility of Τ cells and В 
cells to CY-A,15 dose-dependent inhibition 
could exist within the T-cell lineage as well. 
Following recognition of antigen, clonal 
expansion of cytotoxic Τ cells may be 
suppressed by CY-A, whereas suppressor Τ 
cells are less affected and are able to induce 
long-lasting unresponsiveness after with­
drawal of CY-A treatment. This mechanism 
may be operative in transplantation models 
where lower doses of CY-A are effective, i.e., 
models in which the rejection reaction is less 
violent than in the one used in our study. In 
fact, it has been reported that after CY-A 
treatment in allogeneic bone marrow trans­
plantation in the rat, spleen cells appeared 
that were suppressive in mixed lymphocyte 
reaction against donor cells.12 We conclude 
that the effectiveness of CY-A treatment 
depends on the transplantation model used 
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and that CY-Λ, at least in mice, does not 
induce long-lasting transplantation toler­
ance. 
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CHAPTER 8 

GENERAL DISCUSSION 
The first set of experiments described in this thesis deals with 
the mechanism of immunological enhancement. It was demonstrated 
that IgGl and IgG2 alloantibodies were equally effective in en-
hancement, whereas IgM antibodies were inactive, both in the en-
hancement of skin allografts and in the suppression of the an-
tibody response of nude mice. In addition, a close correlation 
could be established between the enhancing and the opsonizing 
capacities of alloantibodies because enhancing IgGl and IgG2 
antibodies were strongly opsonizing in vivo, whereas non-enhan-
cing IgM antibodies were not. It was further demonstrated that 
monoclonal alloantibodies were ineffective in enhancement, 
whereas the effects of antigen-antibody complexes were inferior 
to the use of antibody alone. 
The design of our experiments was based on previous results from 
our laboratory which demonstrated that F(ab,)2 fragments, with 
similar antigen binding capacities as the enhancing antibodies 
from which they originated, were unable to induce enhancement 
(1,2). This finding, which was subsequently confirmed by others 
(3), showed that enhancement is Fc-dependent. It implied that 
enhancing antibodies do not act by the simple masking of anti-
genic determinants, but that the induction of passive enhance-
ment is an active process. Since enhancement is specific, it 
was also evident that binding of alloantibodies to alloantigen 
is required. Taken together, these results suggested that the 
induction of enhancement might result from the complex forma-
tion of antigen and alloantibody and, in addition, from the 
interaction of the Fc-part of complex-bound alloantibody with 
secondary effector mechanisms. Several models are compatible 
with this view. 
Elimination of passenger cells. It was recently suggested for 
kidney graft enhancement in the rat, that the prolongation of 
graft survival resulted from the opsonization of passenger leu-
kocytes, thereby reducing the immunogenic stimulus (4). At first 
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sight, our results seem to support this hypothesis. We demon-
strated the close correlation between the enhancing and opsoni-
zing capacities of various immunoglobulin (sub)classes, and the 
finding that strongly opsonizing monoclonal antibodies were un-
able to induce enhancement, could be explained by the assumption 
that the specificities analyzed reacted with only a limited num-
ber of immunogenic graft antigens. Nevertheless, other findings 
argue against this mechanism. Firstly, the continuous admini-
stration of alloantibody should improve the enhancement which 
is established by the injection of alloantibody at the time of 
grafting, and this is clearly not the case (5). Secondly, the 
finding that enhancement by anti-class II antibodies in the 
case of class I + class II MHC-differences is nearly as effec-
tive as with an antiserum directed to the total barrier (6) is 
in contrast to the hypothesis, because if only the class II an-
tigens had been removed, one would have expected graft survival 
to be equal to that in combinationswith class I differences on-
ly. The third and most striking evidence against this mechanism 
is the recent demonstration of the enhancement of tumors (7), 
skin, and kidney grafts (8) by anti-TNP antibodies and TNP-
coupled alloantigen, because in this situation enhancing anti-
TNP antibodies do not interfere with the graft antigens them-
selves. 
Activation of suppressor cells. Other explanations for the phe-
nomenon of enhancement focus on the interaction of antigen-an-
tibody complexes with antigen-reactive cells (ARC) of the host. 
Antigen-specific lymphocytes may bind immune complexes consis-
ting of released graft antigen and administered alloantibody, 
and upon binding, the cell may be activated by the interaction 
of the Fc-part of the antibody with Fc-receptors on this lym-
phocyte. In this way suppressor cells could be induced. Indeed, 
the coexistence of enhancing antibodies and suppressor cells 
was demonstrated in mice, treated for active enhancement (9). 
Studies from another laboratory, however, failed to demonstrate 
suppressor cells in rats carrying long term surviving, passive-
ly enhanced, kidney allografts (10). Similarly, our results in 
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nude, T-cell deficient mice argue against a role for T-suppres-
sor cells in the induction of passive enhancement. They also 
argue against the proposition that suppressive antibody inter-
feres with the cooperation of B-cells with T-helper cells 
(11). 
Inaativation of antigen-reaat-Lve cells. Instead of lymphocyte 
activation by the interaction of the Fc-part of enhancing anti-
body with Fc-receptors on these lymphocytes, antigen-antibody 
complexes might inactivate ARC in this way. This mechanism was 
initially suggested for antibody-mediated suppression of the 
humoral response (12), and evidence for this model was provided 
in vitro, by showing that in the absence of T-lymphocytes and 
macrophages, immune complexes could directly suppress the anti-
body response of B-cells (13). Therefore, antigen-antibody 
complexes may exert regulatory influences by the interaction 
of complex-bound antibody with Fc-receptors on antigen-speci-
fic lymphocytes. 
Fc-receptors have been demonstrated on B-cells and subsequent-
ly also on T-cells of various species (14). In man, the pre-
sence on T-cells of receptors for either IgG (FcyR) or IgM 
(FcyR) appeared to be of functional significance, because sup-
pressor cells were shown to carry FcyR, whereas helper T-cells 
carried FcpR (15). Further studies, however, revealed that FcyR 
and FcyR were not stable phenotypes and that their expression 
reflected particular stages of maturation or activation, espe-
cially since switches from FcyR to FcyR were observed (16). The 
functional significance of these markers for the regulation of 
the immune response, therefore, is still unclear, and the rela-
tionship with the phenomenon of antibody-mediated immune sup-
pression remains to be established. 
Binding of antigen-antibody complexes to specific antigen-reac-
tive cells, however, may still result in lymphocyte inactiva-
tion, but by secondary effector mechanisms which are Fc-depen-
dent (complement, antibody-dependent cellular cytotoxicity 
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(ADCC), phagocytosis or other). The similar enhancing activi-
ties of IgGl and IgG2 demonstrate that complement cannot play 
a major role as effector mechanism . The same conclusion was 
recently reached by others, who showed that decomplementation 
of graft recipients did not interfere with enhancement (17). 
Similarly, our observation that IgM was unable to induce enhan-
cement, whereas these antibodies are able to mediate ADCC (18), 
argues against ADCC as a Fc-dependent effector system. By con-
trast, the close correlation between the enhancing and opsoni-
zing capacities of alloantibodies strongly suggests, that anti-
gen-reactive cells (ARC) may be eliminated by phagocytosis. Di-
rect evidence for this phenomenon was provided by Hutchinson, 
who showed that radiolabelled ARC, injected i.V. into recipients 
treated for antibody-mediated immune suppression, were diver-
ted away from the spleen with a simultaneous increased locali-
zation in the liver. This liver diversion was observed with ARC 
specific for sheep red blood cells, and also in the case of tu-
mor and kidney graft enhancement (19). Further support for this 
mechanism was provided by others, who showed that the homing of 
cytotoxic T-lymphocytes to skin allografts in the mouse, was spe-
cifically abrogated under enhancing conditions (20). 
Thus, the sequence of events taking place in the induction of 
enhancement may be visualized as follows. Circulating lympho-
cytes recognize free antigenic determinants in immune complexes 
which consist of administered alloantibody and released graft 
antigens. By this process, they may ignore the graft itself and 
proceed to lymphoid organs where they are eliminated by phago-
cytic cells, or via the circulation, by the Kupffer cells of 
the liver. It may be expected that this process goes on as long 
as these complexes are present. Consequently, pretreatment with 
antigen-antibody complexes may eliminate a certain number of 
cells, but due to recruitment, normal numbers of lymphocytes 
may again circulate at the time of transplantation, resulting 
in normal graft rejection. 
With the implication of antigen-antibody complexes in the in-
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duction of enhancement,it is evident that the nature of complex-
bound antigen plays a crucial role. Antigens may consist of 
passenger cells, but also of molecular H-2 products which are 
shed by passenger leukocytes and by epidermal cells of the graft. 
Clearly, the free antigenic determinants whithin a complex pro-
vide for the interaction with antigen-reactive cells, and the 
number of different molecular antigens displayed within the 
complex, will determine the number of ARC-specificities that 
might be eliminated. All antigenic specificities of the graft 
barrier are expressed by passenger cells, and antibodies bin-
ding to only a few determinants of either class I or class II 
antigens on these leukocytes, may eliminate all ARC-specifici-
ties that respond to the graft barrier. By contrast, a complexed 
molecular H-2 antigen will eliminate only those ARC which are 
directed to that particular antigen, and when these types of 
small complexes would prevail, antibodies against all antigenic 
specificities of the graft barrier should be administered in or-
der to interfere effectively with the induction of the immune 
response. Our results with monoclonal antibodies strongly sug-
gest that this is the case. Since a limited number of specifi-
cities failed to induce enhancement, it is most likely that some 
molecular H-2 products were missed, and that a normal response 
developed against these "uncovered" antigens. 
The same explanation applies when it is assumed that different 
H-2 antigens have different stimulatory capacities, and that 
the type of antigen-reactive cell that is eliminated is of prime 
importance. In general, the immunogenicity of individual H-2 
loci, whether class I or class II, is the same as judged by 
skin graft rejection and MLR-reactivity of appropriate recombi-
nant or H-2 mutant mouse strains (21-23). When class I + class 
II differences exist, however, these effects cumulate to yield 
a stronger response. This stronger response may occur as a re-
sult of summation, or because of an amplification mechanism. 
Evidence for I-region induced amplification of the cytotoxic 
response to class I antigens has been provided in vitro (24). 
Similarly, the superior enhancing capacity of anti-class II as 
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compared to anti-class I sera suggests that I-region encoded 
antigens are the major stimulus for graft rejection when class 
I + class II MHC-differences are present (6). In the light of 
newly discovered H-2 products, it is very well possible that 
the panel of monoclonal antibodies that we tested, did not react 
with strongly stimulatory H-2 antigens. 
We have described experiments dealing with the enhancement of 
mouse skin allografts. In this model, attention is focussed on 
the induction phase of enhancement since prolongation of graft 
survival is modest in comparison with tumor enhancement in the 
mouse, or kidney and heart allograft enhancement in the rat. As 
a consequence, our results should not be viewed as if the eli-
mination of antigen-reactive cells by antigen-antibody complexes 
is the only mechanism which is operative in enhanced animals. 
Different mechanisms may operate in different animals, with 
different grafts and importantly, in different stages of the 
immune response. Nevertheless, our results strongly suggest 
that in the induction phase of enhancement, the opsonization 
of antigen-reactive cells is of major importance. 
Our results with Cyclosporin A (CyA) confirmed the powerful im-
munosuppressive activities of this agent, but they disproved 
the original claims that it could induce specific unresponsive-
ness. Similar findings have now been obtained in other experi-
mental models, where the results with CyA were far superior to 
existing immunosuppressive regimens notably in outbred species 
like the mongrel dog and the pig (25). Recent studies indicate 
that CyA exerts its immunosuppressive effect by interfering 
with the T-cell dependent production of monokines (IL-1) by 
accessory cells, and by blocking the receptor expression for 
these monokines on T-cells, resulting in the abrogation of lym-
phokine (IL-2) production (26,27). In addition, IL-2 receptive 
T-cells were rendered unresponsive to this lymphokine, and this 
sequence of events may explain the high degree of T-cell speci-
ficity of CyA. This specificity may provide new approaches in 
the treatment of T-cell malignancies, since a strong and selec-
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tive cytotoxic effect of CyA has already been demonstrated in 
vitro on various T-cell lines and also on freshly explanted ma-
lignant T-cells (28). For the moment, however, CyA may first 
of all "change the face of transplantation"(29). 
To date, 1400 transplant patients have been treated with CyA, 
the majority receiving a kidney (800) or a bone marrow (400) 
graft (30). In addition, large scale controlled studies are con-
ducted at present in Europe and in North America, and the re-
sults thusfar, indicate superior graft survival in comparison 
with conventional therapy. There is, therefore, every reason 
for a"cautious optimism" (30) regarding the promises of CyA, 
although various side-effects, especially its nephrotoxicity, 
have to be taken most seriously. Nevertheless, CyA offers anew 
perspective for clinical transplantation, and it is hoped that 
this agent, or derivatives thereof, may obviate or at least di-
minish the use of steroids in the near future. 
Our studies concerning the mechanism of enhancement offer new 
prospects in clinical transplantation as well, because it was 
demonstrated that non-complement fixing, and thus non-destruc-
tive IgGl antibodies were as effective as IgG2 antibodies in 
the induction of enhancement. However, although knowledge about 
the world of complex regulatory circuits in immunological pro-
cesses has expanded considerably, it is still characterized by 
great blanks. Isolated in vitro systems may have adequately 
been described, but the interplay of initiating, augmenting, 
helper, and suppressor cells in vivo, and their interactions 
with B-cells, and with idiotypic and anti-idiotypic antibodies, 
remains largely unknown. Only by further experimentation can 
more insight be provided into the astonishing ways the immune 
system operates and thus, into the possibilities to manipulate 
the immune response specifically. 
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SAMENVATTING 
De studies die in dit proefschrift zijn beschreven hadden tot 
doel om meer inzicht te verkrijgen in het werkingsmechanisme 
van twee experimentele immunosuppressieve behandelingen. Het 
eerste gedeelte handelt over de transplantaat-beschermende in­
vloed van specifieke anti-donor antistoffen (Immunologische En­
hancement) , en het tweede over Cyclosporine A, een schimmelme-
taboliet. De studies werden uitgevoerd in een muizemodel, waar­
bij donor staarthuid werd getransplanteerd op de flank van ont­
vanger muizen. Het immunosuppressief effect van de behandeling­
en werd bepaald aan de hand van de transplantaatoverleving of 
door het meten van de door de ontvanger gevormde antistoffen. 
Voorgaande onderzoekingen en literatuurgegevens van anderen leg­
den de basis voor de hypothese dat immunologische enhancement 
door passief toegediende antistoffen tot stand komt via elimi­
natie van antigeen-reactieve lymfосуten. Onder normale omstan­
digheden zal kontakt met antigeen met zijn specifieke antigeen-
reaktieve cel leiden tot stimulatie en clonale proliferatie, 
maar bij gelijktijdige aanwezigheid van voor het antigeen spe­
cifieke antistoffen ontstaan er immuuncomplexen die kunnen lei­
den tot een Fc-afhankelijke uitdoving, waardoor de reaktie spe­
cifiek wordt onderdrukt. Om deze hypothese te onderbouwen werd 
enerzijds het immunosuppressief effect van antigeen-antistof 
complexen bestudeerd, anderzijds werd gepoogd inzicht te ver­
krijgen in de Fc-afhankelijke effektor mechanismen die bij de 
eliminatie van antigeen-reaktieve cellen betrokken zouden kun­
nen zijn. 
Uit de analyse van het immunosuppressief effekt van verschil­
lende antistof (sub)klassen bleek dat IgGl en IgG2 antistoffen 
even effektief waren, maar dat de IgM-klasse noch voor de nor­
male cellulaire respons, noch voor de humorale respons in thy-
mus-loze muizen immunosuppressie kon induceren. Tevens bleek 
dat het vermogen om enhancement te induceren nauw correleerde 
met de opsonizerende eigenschappen van enhancing antistoffen. 
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De rol van antigeen-antistof complexen en de samenstelling daar-
van werd onderzocht met monoclonale antistoffen,en met in vitro 
en in vivo geformeerde immuuncomplexen. Echter, geen van de ge-
teste monoclonale antistoffen, noch combinaties daarvan indu-
ceerde enhancement, terwijl ook met immuuncomplexen bestaande 
uit toegediend donor-antigeen en conventionele alloantistoffen 
geen enhancement kon worden geïnduceerd. 
In het licht van het mechanisme van enhancement wijzen deze re-
sultaten erop dat antistof-gemedieerde immunosuppressie niet 
behoeft te verlopen via de inductie van T-suppressor cellen, 
maar direkt, en het meest effektief ingrijpt in de aanloop van 
de immuunrespons. Gezien de specificiteit van enhancement moet 
worden aangenomen dat antigeen-antistof complexen hierbij een 
rol spelen, maar de samenstelling ervan, en het type antigeen-
reaktieve cel dat in de inductie van enhancement het primaire 
doelwit vormt, is niet duidelijk. Wel kan worden geconcludeerd 
dat de Fc-afhankelijkheid van enhancement betrekking heeft op 
het vermogen van de antistof om fagocytose te initiëren, en 
daarmee ondersteunen onze resultaten de hypothese dat enhance-
ment tot stand komt via de eliminatie van specifiek antigeen-
reaktieve cellen. 
Onze bevindingen met Cyclosporine A wijzen er op dat dit mid-
del een sterke, hoewel niet-specifieke, immunosuppressie kan in-
duceren. Deze gegevens zijn inmiddels bevestigd door andere 
laboratoria, en de resultaten van recente klinische trials in 
verschillende centra geven aan dat Cyclosporine A, of hieraan 
verwante middelen, in de nabije toekomst het gebruik van Ste-
roiden overbodig zou kunnen maken. Echter, ook onze studies 
naar het mechanisme van enhancement geven een nieuw perspek-
tief voor de klinische transplantatie, omdat kon worden aange-
toond dat niet-complement bindende, en dus niet-destruktieve 
IgGl antistoffen even effektief zijn als IgG2 antistoffen in 
de inductie van enhancement. 
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WOORDEN VAN DANK 
Dit proefschrift is tot stand gekomen dankzij de vruchtbare sa-
menwerking van de medewerkers van de afdeling Nierziekten, met 
name op het laboratorium, en de inzet van velen daarbuiten. 
De discussies over de resultaten van het onderzoek, het geza-
menlijk congresbezoek en de diepgaande nabesprekingen daarvan, 
en de betrokkenheid van medewerkers van de afdeling Patholo-
gische Anatomie, vormden een immunologische lego doos waarmee 
naar hartelust gespeeld werd. Dat de ontworpen luchtkastelen 
tot ware proporties werden teruggebracht is te danken aan de 
inzet van allen, maar met name dankzij het solide experimentele 
werk van Wim Tamboer, Truus Rijke, Cor Jacobs, en Jeanne van 
Rijs. Hetzelfde geldt voor Hans Beek, Désirée Jacobs en Peter 
Hendriksen, die in het kader van hun laboratoriumstage bij ver-
schillende aspecten van het onderzoek waren betrokken. Het dier-
experimentele werk kwam tot stand dankzij de voortreffelijke 
inzet van Jacqueline Hagemann en Peter Daamen, in de loop van 
de jaren bijgestaan door Trees Borggreve en Eric Schroevers, 
die voor dit onderzoek alleen al meer dan 500 transplantatie-
groepen inzetten en talloze antisera produceerden en registreer-
den. Ine Cornelissen van het laboratorium Chemische Pathologie 
van de afdeling Pathologische Anatomie was in voorkomende ge-
vallen altijd bereid om op zeer deskundige wijze als "stand-in" 
te funktioneren. Jan Koedam, Lia van de Vorle-Houben, dhr. G.M. 
Busser en de overige medewerkers van afdeling IV en van de 
boerderij van het Centraal Dieren Laboratorium waren hier ten 
nauwste bij betrokken vanwege hun zorg voor de proefdieren en 
hun hulp. Hetzelfde geldt voor Gerrie Grutters die het radio-
actieve werk in de muis in goede banen wist te leiden. Hierbij 
wil ik tevens Magda van de Manacker en mevr. A.C. Felten-Chardon 
betrekken die ik erkentelijk ben voor hun hulp bij het verkrij-
gen van radioactieve chemicaliën. De figuren in dit proefschrift 
werden met de grootste zorg getekend door medewerkers van de 
afdeling Medische Illustratie (hoofd: dhr. W.P.J. Maas), en de 
foto's werden vervaardigd door medewerkers van de afdeling Me-
dische Fotografie (hoofd: dhr. A.T.A. Reynen). De medewerkers 
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van deze afdelingen ben ik ook erkentelijk voor het vervaardi-
gen van grote aantallen dia's, met name Dhr. A.T. van Uden voor 
zijn verzorging van het instant-werk en de posters. De heer E. 
de Graaff (hoofd Medische Bibliotheek) en zijn medewerkers ben 
ik dankbaar voor hun hulp bij het verzamelen van de literatuur; 
dit geldt met name Gerry Hermkens van de bibliotheek Medische 
Microbiologie. Het typen van dit manuscript en de talrijke ver-
sies daarvoor werd met grote toewijding en nauwkeurigheid ver-
richt door Ilse Hilgers-Biermans en Erna Kokke; dankzij hun in-
spanningen werden de krappe tijdslimieten ook nu weer gehaald. 
Ik vind het bijzonder leuk dat Margriet Lems de omslag wilde 
verzorgen, en met het resultaat feliciteer ik haar en mezelf. 
Tenslotte wil ik Barbara, mijn lief, bedanken voor de essentië-
le inbreng die zij in de loop der jaren in dit werk heeft ge-
had; haar idee voor de omslag valt daarbij in het niet. 
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STELLINGEN 
I 
IgM antistoffen hebben geen transplantaatbeschermende (enhan-
cing) werking en missen tevens het vermogen om te opsonizeren. 
II 
De transplantaatbeschermende effekten van IgGl en lgG2 allo-
antistoffen van de muis zijn vergelijkbaar en nauw gecorreleerd 
met hun opsonizerende aktiviteit. 
III 
Het vermogen van alloantistoffen om te opsonizeren is een voor-
waarde, maar geen garantie voor hun transplantaatbeschermende 
aktiviteit. 
IV 
Complexen van passagere donor leukocyten en transplantaatbe-
schermende antistoffen spelen geen rol in de induktie van Im-
munologische Enhancement van huid-allotransplantaten in de 
muis. 
V 
Bij het testen van Immunologische Enhancement in pre-klinische 
modellen van proefdieren met een adequaat complement systeem 
verdient het gebruik van niet-complement bindende IgG allo-
antistof f en de voorkeur boven de toepassing van anti-Ia sera, 
teneinde een interferentie door antistof gemediëerde destruk-
tie uit te sluiten. 
Marquet RL, van Es AA, Heystek GA et al: Transplantation 25: 188, 1978 
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Gezien de antistof respons die in thymusloze nu/nu muizen 
wordt opgeroepen moeten tenminste de klasse I H-2 antigenen 
als thymus onafhankelijk worden gekenmerkt. 
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Indien bij klinische niertransplantaties Cyclosporine A wordt 
toegepast moet dit middel gedurende de eerste 10 dagen post­
operatief via continue intraveneuze infusie worden toegediend, 
en wel in zodanige hoeveelheden dat de bloedspiegel op 200 
ng/ml wordt gehouden om voldoende immunosuppressie te garande­
ren met minimale toxische effekten. 
White DJG, Calne RY: Transplant Proc 15: in press 
Kahan BD, Ried M, Newburger J: Transplant Proc 15: in press 
VIII 
Onder invloed van een cellulaire immuunrespons komen klasse II 
H-2 antigenen tot expressie op het capillaire vaatendotheel 
van huid-allotransplantaten bij de muis. Dit suggereert dat 
het vaatendotheel, en niet de passagere Ia-positieve leukocyt, 
fungeert als doelwit voor transplantaatafstoting in geval van 
een klasse II transplantatie barriere. 
de Waal RMW, persoonlijke mededeling 
IX 
Het verdient aanbeveling om na te gaan of conjugaten van anti-
geen en cytotoxische geneesmiddelen of toxinen antigeen-speci-
fieke immunosuppressie in vivo kunnen induceren. 
Vitetta ES, Krolick KA, Uhr JW: Immunol Rev 62: 159, 1982 
Volkman DJ, Ahmad A, Fauci AS et al: J Exp Med 156: 634, 1982 
Χ 
De basale mechanismen die ten grondslag liggen aan de induktie 
en de regulatie van de immuunrespons kunnen pas dan begrepen 
worden als een gedetailleerde kennis beschikbaar is van de 
chemische strukturen van de moleculen die de cellulaire inter-
akties van immunocompetente cellen mediëren. 
XI 
De suggestie van Highton et al dat adsorptie met proteine A-
Sepharose van sera van patiënten met Rheumatoide Arthritis in-
formatie geeft over de hoeveelheid circulerende IgG-IgM(Rf) 
complexen is onjuist, omdat ook niet gecomplexeerde IgM(Rf) 
kan binden aan Sepharose-proteine A gebonden IgG. 
Highton J, Panayi GS, Shepherd Ρ et al: Ann Rheum Dis 40: 575, 19Θ1 
Faaber Ρ, persoonlijke mededeling 
XII 
Het feit dat de frequentie van peritonitis bij chronische cy­
clische peritoneaal dialyse (CCPD) lager is dan bij chronische 
ambulante peritoneaal dialyse rechtvaardigt de toepassing van 
CCPD-behandeling ondanks de hogere kosten. 
Diaz-Buxo JA, Farmer CD, Walker PJ et al: Artif Organs 5: 157, 19Θ1 
XIII 
De benaming "in vitro", als tegenhanger van het begrip "in 
vivo", dient vervangen te worden door de term "in plastico". 
XIV 
Het is te betreuren dat de groep Boney M de aanzet tot vernieu­
wing van het kerkelijk lied na de eerste poging met Psalm 137 
niet krachtiger heeft doorgezet. 
Boney M: The rivers of Babyion 
XV 
Voor een heilzaam gebruik van de b i jbe l i s het raadplegen van 
een b i j s l u i t e r onontbeer l i jk . 
Labuschagne CJ: Wat zegt de b i j b e l in GODS naam ?, Boekencentrum, 1977 
Rapport over de aard van het Schrif tgezag "God met o n s " : Kerkinformatie 
113, Leusden, 1981 
XVI 
De benaming "demissionair" voor een kabinet dat slechts lopen-
de zaken behartigt suggereert ten onrechte dat een "missionair" 
kabinet uitsluitend beleidsplannen met visie ontwikkelt. 
XVII 
Door de plaats die promovendi in de corona van de aula van de 
Katholieke Universiteit te Nijmegen innemen, moeten zij zich 
in allerlei bochten wringen om de oppositie op behoorlijke 
wijze van repliek te dienen. 
Simon P.M. Lems Nijmegen, 25 november 1982 


